Search Results For:
- Search results for:
- CEPI
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
GHIAA2019\MapguideSearch Object ( [search_parameters] => Array ( [qs] => CEPI ) [filters] => Array ( [text_search] => CEPI ) [child_filters] => Array ( ) [agreement_args] => [provision_args] => Array ( [post_type] => provision_document [posts_per_page] => -1 [post__in] => Array ( [0] => 8491 [1] => 8490 [2] => 8489 [3] => 8488 [4] => 8487 [5] => 8486 [6] => 8485 [7] => 8484 [8] => 8482 [9] => 8481 [10] => 8480 [11] => 8479 [12] => 8469 [13] => 8468 [14] => 8467 [15] => 8462 [16] => 8461 [17] => 8314 [18] => 8313 [19] => 8312 [20] => 8311 [21] => 8192 [22] => 8191 [23] => 8190 [24] => 8157 [25] => 8152 [26] => 8151 [27] => 8150 [28] => 8143 [29] => 8142 [30] => 8131 [31] => 8130 [32] => 8129 [33] => 8051 [34] => 5782 [35] => 5653 [36] => 5652 [37] => 5427 [38] => 4580 [39] => 4205 [40] => 4204 [41] => 4201 [42] => 4200 [43] => 4141 [44] => 4140 [45] => 4139 [46] => 4138 [47] => 4137 [48] => 4136 [49] => 4135 [50] => 4134 [51] => 4133 [52] => 4131 [53] => 4130 [54] => 4129 [55] => 4128 [56] => 3757 [57] => 3756 [58] => 3755 [59] => 3754 [60] => 3753 [61] => 3751 [62] => 3749 [63] => 3748 [64] => 3747 [65] => 3746 [66] => 3744 [67] => 3743 [68] => 3736 [69] => 3726 [70] => 3725 [71] => 3724 [72] => 3722 [73] => 3493 [74] => 3344 [75] => 3343 [76] => 3342 [77] => 3341 [78] => 3339 [79] => 3338 [80] => 3336 [81] => 3331 [82] => 3329 [83] => 3327 [84] => 3326 [85] => 3323 [86] => 3321 [87] => 3318 [88] => 3316 [89] => 3315 [90] => 2909 [91] => 2908 [92] => 2907 [93] => 2893 [94] => 2892 [95] => 2890 [96] => 2889 [97] => 2885 [98] => 1221 [99] => 1205 [100] => 1204 [101] => 1203 [102] => 1202 [103] => 1159 [104] => 996 [105] => 8491 [106] => 8490 [107] => 8489 [108] => 8488 [109] => 8487 [110] => 8486 [111] => 8485 [112] => 8484 [113] => 8482 [114] => 8481 [115] => 8480 [116] => 8479 [117] => 8469 [118] => 8468 [119] => 8467 [120] => 8462 [121] => 8461 [122] => 8314 [123] => 8313 [124] => 8312 [125] => 8311 [126] => 8192 [127] => 8191 [128] => 8190 [129] => 8157 [130] => 8152 [131] => 8151 [132] => 8150 [133] => 8143 [134] => 8142 [135] => 8131 [136] => 8130 [137] => 8129 [138] => 8051 [139] => 5782 [140] => 5653 [141] => 5652 [142] => 5427 [143] => 4580 [144] => 4205 [145] => 4204 [146] => 4201 [147] => 4200 [148] => 4141 [149] => 4140 [150] => 4139 [151] => 4138 [152] => 4137 [153] => 4136 [154] => 4135 [155] => 4134 [156] => 4133 [157] => 4131 [158] => 4130 [159] => 4129 [160] => 4128 [161] => 3757 [162] => 3756 [163] => 3755 [164] => 3754 [165] => 3753 [166] => 3751 [167] => 3749 [168] => 3748 [169] => 3747 [170] => 3746 [171] => 3744 [172] => 3743 [173] => 3736 [174] => 3726 [175] => 3725 [176] => 3724 [177] => 3722 [178] => 3493 [179] => 3344 [180] => 3343 [181] => 3342 [182] => 3341 [183] => 3339 [184] => 3338 [185] => 3336 [186] => 3331 [187] => 3329 [188] => 3327 [189] => 3326 [190] => 3323 [191] => 3321 [192] => 3318 [193] => 3316 [194] => 3315 [195] => 2909 [196] => 2908 [197] => 2907 [198] => 2893 [199] => 2892 [200] => 2890 [201] => 2889 [202] => 2885 [203] => 1221 [204] => 1205 [205] => 1204 [206] => 1203 [207] => 1202 [208] => 1159 [209] => 996 [210] => 5808 [211] => 4661 [212] => 4147 [213] => 4148 [214] => 4223 [215] => 4222 [216] => 4221 [217] => 4220 [218] => 4219 [219] => 4218 [220] => 4217 [221] => 4216 [222] => 4215 [223] => 4214 [224] => 4213 [225] => 4212 [226] => 4210 [227] => 4209 [228] => 4161 [229] => 4159 [230] => 4158 [231] => 4157 [232] => 4156 [233] => 4155 [234] => 4154 [235] => 4153 [236] => 4152 [237] => 4151 [238] => 4150 [239] => 4149 [240] => 4146 [241] => 3812 [242] => 3810 [243] => 3809 [244] => 3808 [245] => 3807 [246] => 3806 [247] => 3805 [248] => 3804 [249] => 3803 [250] => 3802 [251] => 3801 [252] => 3800 [253] => 3799 [254] => 3798 [255] => 3797 [256] => 3796 ) ) [text_agreement_args] => Array ( [post_type] => agreement [posts_per_page] => -1 [s] => CEPI ) [text_provision_args] => Array ( [post_type] => provision_document [posts_per_page] => -1 [s] => CEPI ) [agreement_ids] => Array ( ) [agreement_q_rslts] => [provision_q_rslts] => [text_agreement_q_rslts] => WP_Query Object ( [query] => Array ( [post_type] => agreement [posts_per_page] => -1 [s] => CEPI ) [query_vars] => Array ( [post_type] => agreement [posts_per_page] => -1 [s] => CEPI [error] => [m] => [p] => 0 [post_parent] => [subpost] => [subpost_id] => [attachment] => [attachment_id] => 0 [name] => [pagename] => [page_id] => 0 [second] => [minute] => [hour] => [day] => 0 [monthnum] => 0 [year] => 0 [w] => 0 [category_name] => [tag] => [cat] => [tag_id] => [author] => [author_name] => [feed] => [tb] => [paged] => 0 [meta_key] => [meta_value] => [preview] => [sentence] => [title] => [fields] => [menu_order] => [embed] => [category__in] => Array ( ) [category__not_in] => Array ( ) [category__and] => Array ( ) [post__in] => Array ( ) [post__not_in] => Array ( ) [post_name__in] => Array ( ) [tag__in] => Array ( ) [tag__not_in] => Array ( ) [tag__and] => Array ( ) [tag_slug__in] => Array ( ) [tag_slug__and] => Array ( ) [post_parent__in] => Array ( ) [post_parent__not_in] => Array ( ) [author__in] => Array ( ) [author__not_in] => Array ( ) [orderby] => title [order] => ASC [suppress_filters] => [ignore_sticky_posts] => [cache_results] => 1 [update_post_term_cache] => 1 [update_menu_item_cache] => [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [nopaging] => 1 [comments_per_page] => 50 [no_found_rows] => [search_terms_count] => 1 [search_terms] => Array ( [0] => CEPI ) [search_orderby_title] => Array ( [0] => wpry_posts.post_title LIKE '{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}CEPI{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}' ) ) [tax_query] => WP_Tax_Query Object ( [queries] => Array ( ) [relation] => AND [table_aliases:protected] => Array ( ) [queried_terms] => Array ( ) [primary_table] => wpry_posts [primary_id_column] => ID ) [meta_query] => WP_Meta_Query Object ( [queries] => Array ( ) [relation] => [meta_table] => [meta_id_column] => [primary_table] => [primary_id_column] => [table_aliases:protected] => Array ( ) [clauses:protected] => Array ( ) [has_or_relation:protected] => ) [date_query] => [request] => SELECT DISTINCT wpry_posts.* FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) ) OR ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) ) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled'))) ORDER BY wpry_posts.post_title ASC [posts] => Array ( [0] => WP_Post Object ( [ID] => 3313 [post_author] => 6 [post_date] => 2021-06-30 10:12:41 [post_date_gmt] => 2021-06-30 10:12:41 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 11:58:03 [post_modified_gmt] => 2021-09-15 11:58:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3313 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4126 [post_author] => 5 [post_date] => 2022-01-28 13:33:11 [post_date_gmt] => 2022-01-28 13:33:11 [post_content] => [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-28 13:33:11 [post_modified_gmt] => 2022-01-28 13:33:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=4126 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2882 [post_author] => 6 [post_date] => 2021-05-14 14:03:29 [post_date_gmt] => 2021-05-14 14:03:29 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 11:58:31 [post_modified_gmt] => 2021-09-15 11:58:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2882 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3719 [post_author] => 5 [post_date] => 2021-08-23 11:02:40 [post_date_gmt] => 2021-08-23 11:02:40 [post_content] => [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 11:58:51 [post_modified_gmt] => 2021-09-15 11:58:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3719 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 8049 [post_author] => 5 [post_date] => 2022-12-12 08:37:47 [post_date_gmt] => 2022-12-12 08:37:47 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement [to_ping] => [pinged] => [post_modified] => 2022-12-12 08:37:47 [post_modified_gmt] => 2022-12-12 08:37:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=8049 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 994 [post_author] => 7 [post_date] => 2020-05-18 19:52:27 [post_date_gmt] => 2020-05-18 19:52:27 [post_content] => [post_title] => CEPI CfP3i Vaccine Funding Agreement Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 11:59:18 [post_modified_gmt] => 2021-09-15 11:59:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=994 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 6 [current_post] => -1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 3313 [post_author] => 6 [post_date] => 2021-06-30 10:12:41 [post_date_gmt] => 2021-06-30 10:12:41 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 11:58:03 [post_modified_gmt] => 2021-09-15 11:58:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3313 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 6 [max_num_pages] => 0 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => 1 [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => 1 [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => 1 [query_vars_hash:WP_Query:private] => b07b72d0f5293e8069c8a04c212072a7 [query_vars_changed:WP_Query:private] => 1 [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => Array ( [0] => about [1] => an [2] => are [3] => as [4] => at [5] => be [6] => by [7] => com [8] => for [9] => from [10] => how [11] => in [12] => is [13] => it [14] => of [15] => on [16] => or [17] => that [18] => the [19] => this [20] => to [21] => was [22] => what [23] => when [24] => where [25] => who [26] => will [27] => with [28] => www ) [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) ) [text_provision_q_rslts] => WP_Query Object ( [query] => Array ( [post_type] => provision_document [posts_per_page] => -1 [s] => CEPI ) [query_vars] => Array ( [post_type] => provision_document [posts_per_page] => -1 [s] => CEPI [error] => [m] => [p] => 0 [post_parent] => [subpost] => [subpost_id] => [attachment] => [attachment_id] => 0 [name] => [pagename] => [page_id] => 0 [second] => [minute] => [hour] => [day] => 0 [monthnum] => 0 [year] => 0 [w] => 0 [category_name] => [tag] => [cat] => [tag_id] => [author] => [author_name] => [feed] => [tb] => [paged] => 0 [meta_key] => [meta_value] => [preview] => [sentence] => [title] => [fields] => [menu_order] => [embed] => [category__in] => Array ( ) [category__not_in] => Array ( ) [category__and] => Array ( ) [post__in] => Array ( ) [post__not_in] => Array ( ) [post_name__in] => Array ( ) [tag__in] => Array ( ) [tag__not_in] => Array ( ) [tag__and] => Array ( ) [tag_slug__in] => Array ( ) [tag_slug__and] => Array ( ) [post_parent__in] => Array ( ) [post_parent__not_in] => Array ( ) [author__in] => Array ( ) [author__not_in] => Array ( ) [suppress_filters] => [ignore_sticky_posts] => [cache_results] => 1 [update_post_term_cache] => 1 [update_menu_item_cache] => [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [nopaging] => 1 [comments_per_page] => 50 [no_found_rows] => [search_terms_count] => 1 [search_terms] => Array ( [0] => CEPI ) [search_orderby_title] => Array ( [0] => wpry_posts.post_title LIKE '{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}CEPI{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}' ) [order] => DESC ) [tax_query] => WP_Tax_Query Object ( [queries] => Array ( ) [relation] => AND [table_aliases:protected] => Array ( ) [queried_terms] => Array ( ) [primary_table] => wpry_posts [primary_id_column] => ID ) [meta_query] => WP_Meta_Query Object ( [queries] => Array ( ) [relation] => [meta_table] => [meta_id_column] => [primary_table] => [primary_id_column] => [table_aliases:protected] => Array ( ) [clauses:protected] => Array ( ) [has_or_relation:protected] => ) [date_query] => [request] => SELECT DISTINCT wpry_posts.* FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) ) OR ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) ) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled'))) ORDER BY wpry_posts.post_title LIKE '{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}CEPI{1c354f56477a22bedee6bff4d68d57bde87907e2ecf8db5d5c39d8fc7c20e85f}' DESC, wpry_posts.post_date DESC [posts] => Array ( [0] => WP_Post Object ( [ID] => 8491 [post_author] => 5 [post_date] => 2023-01-19 11:34:54 [post_date_gmt] => 2023-01-19 11:34:54 [post_content] => [post_title] => CEPI CfP3i Vaccine Funding Agreement Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-vaccine-funding-agreement-template [to_ping] => [pinged] => [post_modified] => 2023-01-19 11:34:54 [post_modified_gmt] => 2023-01-19 11:34:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8491 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 8490 [post_author] => 5 [post_date] => 2023-01-19 11:11:46 [post_date_gmt] => 2023-01-19 11:11:46 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-01-19 11:11:46 [post_modified_gmt] => 2023-01-19 11:11:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8490 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 8489 [post_author] => 5 [post_date] => 2023-01-19 10:44:52 [post_date_gmt] => 2023-01-19 10:44:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:44:52 [post_modified_gmt] => 2023-01-19 10:44:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8489 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 8488 [post_author] => 5 [post_date] => 2023-01-19 10:15:15 [post_date_gmt] => 2023-01-19 10:15:15 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:15:15 [post_modified_gmt] => 2023-01-19 10:15:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8488 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 8487 [post_author] => 5 [post_date] => 2023-01-19 09:59:54 [post_date_gmt] => 2023-01-19 09:59:54 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:59:54 [post_modified_gmt] => 2023-01-19 09:59:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8487 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 8486 [post_author] => 5 [post_date] => 2023-01-19 09:46:36 [post_date_gmt] => 2023-01-19 09:46:36 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:46:36 [post_modified_gmt] => 2023-01-19 09:46:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8486 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [6] => WP_Post Object ( [ID] => 8485 [post_author] => 5 [post_date] => 2023-01-19 09:39:38 [post_date_gmt] => 2023-01-19 09:39:38 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:39:38 [post_modified_gmt] => 2023-01-19 09:39:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8485 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [7] => WP_Post Object ( [ID] => 8484 [post_author] => 5 [post_date] => 2023-01-19 09:17:50 [post_date_gmt] => 2023-01-19 09:17:50 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:17:50 [post_modified_gmt] => 2023-01-19 09:17:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8484 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [8] => WP_Post Object ( [ID] => 8482 [post_author] => 5 [post_date] => 2023-01-18 16:32:52 [post_date_gmt] => 2023-01-18 16:32:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-18 16:32:52 [post_modified_gmt] => 2023-01-18 16:32:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8482 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [9] => WP_Post Object ( [ID] => 8481 [post_author] => 5 [post_date] => 2023-01-18 15:49:38 [post_date_gmt] => 2023-01-18 15:49:38 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-19 12:07:24 [post_modified_gmt] => 2023-01-19 12:07:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8481 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [10] => WP_Post Object ( [ID] => 8480 [post_author] => 5 [post_date] => 2023-01-17 17:53:00 [post_date_gmt] => 2023-01-17 17:53:00 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:53:00 [post_modified_gmt] => 2023-01-17 17:53:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8480 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [11] => WP_Post Object ( [ID] => 8479 [post_author] => 5 [post_date] => 2023-01-17 17:35:45 [post_date_gmt] => 2023-01-17 17:35:45 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:35:45 [post_modified_gmt] => 2023-01-17 17:35:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8479 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [12] => WP_Post Object ( [ID] => 8469 [post_author] => 5 [post_date] => 2023-01-13 13:35:47 [post_date_gmt] => 2023-01-13 13:35:47 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19 [to_ping] => [pinged] => [post_modified] => 2023-01-13 13:35:47 [post_modified_gmt] => 2023-01-13 13:35:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8469 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [13] => WP_Post Object ( [ID] => 8468 [post_author] => 5 [post_date] => 2023-01-11 14:35:38 [post_date_gmt] => 2023-01-11 14:35:38 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-11 14:54:13 [post_modified_gmt] => 2023-01-11 14:54:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8468 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [14] => WP_Post Object ( [ID] => 8467 [post_author] => 5 [post_date] => 2023-01-11 14:29:13 [post_date_gmt] => 2023-01-11 14:29:13 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-11 14:36:41 [post_modified_gmt] => 2023-01-11 14:36:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8467 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [15] => WP_Post Object ( [ID] => 8462 [post_author] => 5 [post_date] => 2023-01-10 12:12:52 [post_date_gmt] => 2023-01-10 12:12:52 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-10 12:21:16 [post_modified_gmt] => 2023-01-10 12:21:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8462 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [16] => WP_Post Object ( [ID] => 8461 [post_author] => 5 [post_date] => 2023-01-10 09:08:41 [post_date_gmt] => 2023-01-10 09:08:41 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 09:17:07 [post_modified_gmt] => 2023-01-10 09:17:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8461 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [17] => WP_Post Object ( [ID] => 8314 [post_author] => 5 [post_date] => 2022-12-13 11:46:36 [post_date_gmt] => 2022-12-13 11:46:36 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-12-13 11:46:36 [post_modified_gmt] => 2022-12-13 11:46:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8314 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [18] => WP_Post Object ( [ID] => 8313 [post_author] => 5 [post_date] => 2022-12-13 10:48:56 [post_date_gmt] => 2022-12-13 10:48:56 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-12-13 10:48:56 [post_modified_gmt] => 2022-12-13 10:48:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8313 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [19] => WP_Post Object ( [ID] => 8312 [post_author] => 5 [post_date] => 2022-12-13 10:35:08 [post_date_gmt] => 2022-12-13 10:35:08 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-12-13 10:35:08 [post_modified_gmt] => 2022-12-13 10:35:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8312 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [20] => WP_Post Object ( [ID] => 8311 [post_author] => 5 [post_date] => 2022-12-13 10:09:44 [post_date_gmt] => 2022-12-13 10:09:44 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-12-13 10:09:44 [post_modified_gmt] => 2022-12-13 10:09:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8311 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [21] => WP_Post Object ( [ID] => 8192 [post_author] => 5 [post_date] => 2022-12-13 09:04:26 [post_date_gmt] => 2022-12-13 09:04:26 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-12-13 09:05:52 [post_modified_gmt] => 2022-12-13 09:05:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8192 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [22] => WP_Post Object ( [ID] => 8191 [post_author] => 5 [post_date] => 2022-12-12 16:19:19 [post_date_gmt] => 2022-12-12 16:19:19 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:55:07 [post_modified_gmt] => 2022-12-13 12:55:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8191 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [23] => WP_Post Object ( [ID] => 8190 [post_author] => 5 [post_date] => 2022-12-12 15:29:46 [post_date_gmt] => 2022-12-12 15:29:46 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:05:30 [post_modified_gmt] => 2022-12-14 13:05:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8190 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [24] => WP_Post Object ( [ID] => 8157 [post_author] => 5 [post_date] => 2022-12-12 15:23:50 [post_date_gmt] => 2022-12-12 15:23:50 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:06:57 [post_modified_gmt] => 2023-03-28 14:06:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [25] => WP_Post Object ( [ID] => 8152 [post_author] => 5 [post_date] => 2022-12-12 12:04:21 [post_date_gmt] => 2022-12-12 12:04:21 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:56:37 [post_modified_gmt] => 2022-12-13 12:56:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [26] => WP_Post Object ( [ID] => 8151 [post_author] => 5 [post_date] => 2022-12-12 11:56:08 [post_date_gmt] => 2022-12-12 11:56:08 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-12-13 13:04:22 [post_modified_gmt] => 2022-12-13 13:04:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [27] => WP_Post Object ( [ID] => 8150 [post_author] => 5 [post_date] => 2022-12-12 11:21:26 [post_date_gmt] => 2022-12-12 11:21:26 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-12-12 11:48:09 [post_modified_gmt] => 2022-12-12 11:48:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [28] => WP_Post Object ( [ID] => 8143 [post_author] => 5 [post_date] => 2022-12-12 11:10:19 [post_date_gmt] => 2022-12-12 11:10:19 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-12-12 11:10:19 [post_modified_gmt] => 2022-12-12 11:10:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8143 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [29] => WP_Post Object ( [ID] => 8142 [post_author] => 5 [post_date] => 2022-12-12 10:40:31 [post_date_gmt] => 2022-12-12 10:40:31 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:57:50 [post_modified_gmt] => 2022-12-13 12:57:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8142 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [30] => WP_Post Object ( [ID] => 8131 [post_author] => 5 [post_date] => 2022-12-12 09:57:36 [post_date_gmt] => 2022-12-12 09:57:36 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:49:55 [post_modified_gmt] => 2022-12-13 12:49:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [31] => WP_Post Object ( [ID] => 8130 [post_author] => 5 [post_date] => 2022-12-12 09:34:49 [post_date_gmt] => 2022-12-12 09:34:49 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:51:49 [post_modified_gmt] => 2022-12-13 12:51:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [32] => WP_Post Object ( [ID] => 8129 [post_author] => 5 [post_date] => 2022-12-12 08:55:53 [post_date_gmt] => 2022-12-12 08:55:53 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:45:31 [post_modified_gmt] => 2022-12-13 12:45:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [33] => WP_Post Object ( [ID] => 8051 [post_author] => 5 [post_date] => 2022-12-12 08:39:19 [post_date_gmt] => 2022-12-12 08:39:19 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:54:45 [post_modified_gmt] => 2023-01-10 13:54:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8051 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [34] => WP_Post Object ( [ID] => 5782 [post_author] => 5 [post_date] => 2022-09-16 07:28:56 [post_date_gmt] => 2022-09-16 07:28:56 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:52:08 [post_modified_gmt] => 2023-01-10 13:52:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5782 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [35] => WP_Post Object ( [ID] => 5653 [post_author] => 5 [post_date] => 2022-08-25 12:56:30 [post_date_gmt] => 2022-08-25 12:56:30 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 12:24:08 [post_modified_gmt] => 2023-01-10 12:24:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5653 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [36] => WP_Post Object ( [ID] => 5652 [post_author] => 5 [post_date] => 2022-08-25 12:26:53 [post_date_gmt] => 2022-08-25 12:26:53 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:46:10 [post_modified_gmt] => 2023-01-10 11:46:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5652 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [37] => WP_Post Object ( [ID] => 5427 [post_author] => 5 [post_date] => 2022-07-22 15:20:29 [post_date_gmt] => 2022-07-22 15:20:29 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-05 13:37:17 [post_modified_gmt] => 2023-01-05 13:37:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5427 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [38] => WP_Post Object ( [ID] => 4580 [post_author] => 5 [post_date] => 2022-03-31 14:34:38 [post_date_gmt] => 2022-03-31 14:34:38 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:02:54 [post_modified_gmt] => 2023-01-05 14:02:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4580 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [39] => WP_Post Object ( [ID] => 4205 [post_author] => 5 [post_date] => 2022-02-28 15:24:19 [post_date_gmt] => 2022-02-28 15:24:19 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:59:13 [post_modified_gmt] => 2022-10-12 12:59:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4205 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [40] => WP_Post Object ( [ID] => 4204 [post_author] => 5 [post_date] => 2022-02-28 14:53:11 [post_date_gmt] => 2022-02-28 14:53:11 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:07:32 [post_modified_gmt] => 2022-12-14 13:07:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4204 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [41] => WP_Post Object ( [ID] => 4201 [post_author] => 5 [post_date] => 2022-02-28 13:33:22 [post_date_gmt] => 2022-02-28 13:33:22 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:13:57 [post_modified_gmt] => 2023-01-10 13:13:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4201 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [42] => WP_Post Object ( [ID] => 4200 [post_author] => 5 [post_date] => 2022-02-28 13:13:29 [post_date_gmt] => 2022-02-28 13:13:29 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:13:52 [post_modified_gmt] => 2022-10-12 11:13:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4200 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [43] => WP_Post Object ( [ID] => 4141 [post_author] => 5 [post_date] => 2022-01-31 14:31:23 [post_date_gmt] => 2022-01-31 14:31:23 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:40:20 [post_modified_gmt] => 2023-01-10 10:40:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4141 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [44] => WP_Post Object ( [ID] => 4140 [post_author] => 5 [post_date] => 2022-01-31 14:22:03 [post_date_gmt] => 2022-01-31 14:22:03 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:54:15 [post_modified_gmt] => 2023-01-10 10:54:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4140 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [45] => WP_Post Object ( [ID] => 4139 [post_author] => 5 [post_date] => 2022-01-31 14:18:32 [post_date_gmt] => 2022-01-31 14:18:32 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:58:00 [post_modified_gmt] => 2023-01-10 10:58:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4139 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [46] => WP_Post Object ( [ID] => 4138 [post_author] => 5 [post_date] => 2022-01-31 14:09:33 [post_date_gmt] => 2022-01-31 14:09:33 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:59:39 [post_modified_gmt] => 2023-01-10 10:59:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4138 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [47] => WP_Post Object ( [ID] => 4137 [post_author] => 5 [post_date] => 2022-01-31 13:53:37 [post_date_gmt] => 2022-01-31 13:53:37 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:02:20 [post_modified_gmt] => 2023-01-10 11:02:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4137 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [48] => WP_Post Object ( [ID] => 4136 [post_author] => 5 [post_date] => 2022-01-31 13:42:47 [post_date_gmt] => 2022-01-31 13:42:47 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:01:51 [post_modified_gmt] => 2023-01-10 11:01:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4136 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [49] => WP_Post Object ( [ID] => 4135 [post_author] => 5 [post_date] => 2022-01-31 13:25:08 [post_date_gmt] => 2022-01-31 13:25:08 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:59:11 [post_modified_gmt] => 2023-01-10 10:59:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4135 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [50] => WP_Post Object ( [ID] => 4134 [post_author] => 5 [post_date] => 2022-01-31 12:56:28 [post_date_gmt] => 2022-01-31 12:56:28 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:58:24 [post_modified_gmt] => 2023-01-10 10:58:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4134 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [51] => WP_Post Object ( [ID] => 4133 [post_author] => 5 [post_date] => 2022-01-31 12:22:56 [post_date_gmt] => 2022-01-31 12:22:56 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:56:11 [post_modified_gmt] => 2023-01-10 10:56:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4133 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [52] => WP_Post Object ( [ID] => 4131 [post_author] => 5 [post_date] => 2022-01-29 16:21:19 [post_date_gmt] => 2022-01-29 16:21:19 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:56:47 [post_modified_gmt] => 2023-01-10 10:56:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [53] => WP_Post Object ( [ID] => 4130 [post_author] => 5 [post_date] => 2022-01-29 15:34:50 [post_date_gmt] => 2022-01-29 15:34:50 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:57:20 [post_modified_gmt] => 2023-01-10 10:57:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [54] => WP_Post Object ( [ID] => 4129 [post_author] => 5 [post_date] => 2022-01-28 14:43:06 [post_date_gmt] => 2022-01-28 14:43:06 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:53:31 [post_modified_gmt] => 2023-01-10 10:53:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [55] => WP_Post Object ( [ID] => 4128 [post_author] => 5 [post_date] => 2022-01-28 13:38:44 [post_date_gmt] => 2022-01-28 13:38:44 [post_content] => [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:07:15 [post_modified_gmt] => 2023-01-10 11:07:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4128 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [56] => WP_Post Object ( [ID] => 3757 [post_author] => 5 [post_date] => 2021-08-25 08:42:34 [post_date_gmt] => 2021-08-25 08:42:34 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:47:08 [post_modified_gmt] => 2023-01-11 15:47:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3757 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [57] => WP_Post Object ( [ID] => 3756 [post_author] => 5 [post_date] => 2021-08-25 08:10:37 [post_date_gmt] => 2021-08-25 08:10:37 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:39:31 [post_modified_gmt] => 2023-01-11 15:39:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3756 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [58] => WP_Post Object ( [ID] => 3755 [post_author] => 5 [post_date] => 2021-08-25 07:55:51 [post_date_gmt] => 2021-08-25 07:55:51 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:24:11 [post_modified_gmt] => 2023-01-19 09:24:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3755 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [59] => WP_Post Object ( [ID] => 3754 [post_author] => 5 [post_date] => 2021-08-24 13:43:37 [post_date_gmt] => 2021-08-24 13:43:37 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:59:38 [post_modified_gmt] => 2023-01-12 13:59:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3754 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [60] => WP_Post Object ( [ID] => 3753 [post_author] => 5 [post_date] => 2021-08-24 13:14:41 [post_date_gmt] => 2021-08-24 13:14:41 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:13:40 [post_modified_gmt] => 2023-01-19 10:13:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3753 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [61] => WP_Post Object ( [ID] => 3751 [post_author] => 5 [post_date] => 2021-08-24 12:54:56 [post_date_gmt] => 2021-08-24 12:54:56 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:20:29 [post_modified_gmt] => 2023-01-12 13:20:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3751 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [62] => WP_Post Object ( [ID] => 3749 [post_author] => 5 [post_date] => 2021-08-24 12:40:53 [post_date_gmt] => 2021-08-24 12:40:53 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:33:44 [post_modified_gmt] => 2023-01-12 13:33:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3749 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [63] => WP_Post Object ( [ID] => 3748 [post_author] => 5 [post_date] => 2021-08-24 12:31:07 [post_date_gmt] => 2021-08-24 12:31:07 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-11 14:17:38 [post_modified_gmt] => 2023-01-11 14:17:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3748 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [64] => WP_Post Object ( [ID] => 3747 [post_author] => 5 [post_date] => 2021-08-24 11:12:07 [post_date_gmt] => 2021-08-24 11:12:07 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:28:33 [post_modified_gmt] => 2023-01-11 15:28:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3747 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [65] => WP_Post Object ( [ID] => 3746 [post_author] => 5 [post_date] => 2021-08-24 10:45:05 [post_date_gmt] => 2021-08-24 10:45:05 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:55:51 [post_modified_gmt] => 2023-01-11 15:55:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3746 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [66] => WP_Post Object ( [ID] => 3744 [post_author] => 5 [post_date] => 2021-08-24 10:32:54 [post_date_gmt] => 2021-08-24 10:32:54 [post_content] => [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:06:21 [post_modified_gmt] => 2023-03-28 14:06:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3744 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [67] => WP_Post Object ( [ID] => 3743 [post_author] => 5 [post_date] => 2021-08-24 10:19:00 [post_date_gmt] => 2021-08-24 10:19:00 [post_content] => [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:53:13 [post_modified_gmt] => 2023-01-11 15:53:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3743 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [68] => WP_Post Object ( [ID] => 3736 [post_author] => 5 [post_date] => 2021-08-24 07:47:09 [post_date_gmt] => 2021-08-24 07:47:09 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-13 14:46:43 [post_modified_gmt] => 2023-01-13 14:46:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3736 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [69] => WP_Post Object ( [ID] => 3726 [post_author] => 5 [post_date] => 2021-08-23 16:13:39 [post_date_gmt] => 2021-08-23 16:13:39 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:23:48 [post_modified_gmt] => 2023-01-11 15:23:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3726 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [70] => WP_Post Object ( [ID] => 3725 [post_author] => 5 [post_date] => 2021-08-23 13:56:41 [post_date_gmt] => 2021-08-23 13:56:41 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:50:35 [post_modified_gmt] => 2023-01-11 15:50:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3725 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [71] => WP_Post Object ( [ID] => 3724 [post_author] => 5 [post_date] => 2021-08-23 13:11:07 [post_date_gmt] => 2021-08-23 13:11:07 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:27:12 [post_modified_gmt] => 2023-01-11 15:27:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3724 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [72] => WP_Post Object ( [ID] => 3722 [post_author] => 5 [post_date] => 2021-08-23 12:12:50 [post_date_gmt] => 2021-08-23 12:12:50 [post_content] => [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:42:28 [post_modified_gmt] => 2023-01-11 15:42:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3722 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [73] => WP_Post Object ( [ID] => 3493 [post_author] => 5 [post_date] => 2021-08-10 11:15:39 [post_date_gmt] => 2021-08-10 11:15:39 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 14:19:31 [post_modified_gmt] => 2023-01-10 14:19:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3493 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [74] => WP_Post Object ( [ID] => 3344 [post_author] => 6 [post_date] => 2021-06-30 13:02:36 [post_date_gmt] => 2021-06-30 13:02:36 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-22 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:29:20 [post_modified_gmt] => 2023-01-05 15:29:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3344 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [75] => WP_Post Object ( [ID] => 3343 [post_author] => 6 [post_date] => 2021-06-30 12:57:07 [post_date_gmt] => 2021-06-30 12:57:07 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-21 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:31:21 [post_modified_gmt] => 2023-01-05 15:31:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3343 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [76] => WP_Post Object ( [ID] => 3342 [post_author] => 6 [post_date] => 2021-06-30 12:50:17 [post_date_gmt] => 2021-06-30 12:50:17 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-20 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:05:20 [post_modified_gmt] => 2023-01-05 15:05:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3342 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [77] => WP_Post Object ( [ID] => 3341 [post_author] => 6 [post_date] => 2021-06-30 12:44:43 [post_date_gmt] => 2021-06-30 12:44:43 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-19 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:04:39 [post_modified_gmt] => 2023-01-05 15:04:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3341 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [78] => WP_Post Object ( [ID] => 3339 [post_author] => 6 [post_date] => 2021-06-30 12:37:28 [post_date_gmt] => 2021-06-30 12:37:28 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:27:08 [post_modified_gmt] => 2023-01-12 13:27:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3339 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [79] => WP_Post Object ( [ID] => 3338 [post_author] => 6 [post_date] => 2021-06-30 12:27:08 [post_date_gmt] => 2021-06-30 12:27:08 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:23:29 [post_modified_gmt] => 2023-01-05 14:23:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3338 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [80] => WP_Post Object ( [ID] => 3336 [post_author] => 6 [post_date] => 2021-06-30 12:18:57 [post_date_gmt] => 2021-06-30 12:18:57 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:57:18 [post_modified_gmt] => 2023-01-05 14:57:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3336 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [81] => WP_Post Object ( [ID] => 3331 [post_author] => 6 [post_date] => 2021-06-30 12:09:31 [post_date_gmt] => 2021-06-30 12:09:31 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:55:43 [post_modified_gmt] => 2023-01-05 14:55:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3331 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [82] => WP_Post Object ( [ID] => 3329 [post_author] => 6 [post_date] => 2021-06-30 12:04:02 [post_date_gmt] => 2021-06-30 12:04:02 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-09 13:18:35 [post_modified_gmt] => 2023-01-09 13:18:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3329 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [83] => WP_Post Object ( [ID] => 3327 [post_author] => 6 [post_date] => 2021-06-30 11:47:34 [post_date_gmt] => 2021-06-30 11:47:34 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-05 13:58:59 [post_modified_gmt] => 2023-01-05 13:58:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3327 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [84] => WP_Post Object ( [ID] => 3326 [post_author] => 6 [post_date] => 2021-06-30 11:35:26 [post_date_gmt] => 2021-06-30 11:35:26 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:05:33 [post_modified_gmt] => 2023-03-28 14:05:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3326 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [85] => WP_Post Object ( [ID] => 3323 [post_author] => 6 [post_date] => 2021-06-30 11:15:16 [post_date_gmt] => 2021-06-30 11:15:16 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-09 13:12:53 [post_modified_gmt] => 2023-01-09 13:12:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3323 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [86] => WP_Post Object ( [ID] => 3321 [post_author] => 6 [post_date] => 2021-06-30 11:12:36 [post_date_gmt] => 2021-06-30 11:12:36 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-13-2 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:03:32 [post_modified_gmt] => 2023-01-05 14:03:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3321 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [87] => WP_Post Object ( [ID] => 3318 [post_author] => 6 [post_date] => 2021-06-30 10:46:25 [post_date_gmt] => 2021-06-30 10:46:25 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-10 09:20:27 [post_modified_gmt] => 2023-01-10 09:20:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3318 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [88] => WP_Post Object ( [ID] => 3316 [post_author] => 6 [post_date] => 2021-06-30 10:25:45 [post_date_gmt] => 2021-06-30 10:25:45 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-09 12:51:00 [post_modified_gmt] => 2023-01-09 12:51:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3316 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [89] => WP_Post Object ( [ID] => 3315 [post_author] => 6 [post_date] => 2021-06-30 10:19:01 [post_date_gmt] => 2021-06-30 10:19:01 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:19:23 [post_modified_gmt] => 2023-01-05 14:19:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3315 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [90] => WP_Post Object ( [ID] => 2909 [post_author] => 6 [post_date] => 2021-05-19 15:13:58 [post_date_gmt] => 2021-05-19 15:13:58 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:42:59 [post_modified_gmt] => 2023-01-10 13:42:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2909 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [91] => WP_Post Object ( [ID] => 2908 [post_author] => 6 [post_date] => 2021-05-19 15:08:05 [post_date_gmt] => 2021-05-19 15:08:05 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:40:09 [post_modified_gmt] => 2023-01-10 13:40:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2908 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [92] => WP_Post Object ( [ID] => 2907 [post_author] => 6 [post_date] => 2021-05-19 14:46:20 [post_date_gmt] => 2021-05-19 14:46:20 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-08-12 15:03:09 [post_modified_gmt] => 2022-08-12 15:03:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2907 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [93] => WP_Post Object ( [ID] => 2893 [post_author] => 6 [post_date] => 2021-05-19 14:40:45 [post_date_gmt] => 2021-05-19 14:40:45 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:17:46 [post_modified_gmt] => 2023-03-28 14:17:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2893 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [94] => WP_Post Object ( [ID] => 2892 [post_author] => 6 [post_date] => 2021-05-14 19:30:23 [post_date_gmt] => 2021-05-14 19:30:23 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 14:00:44 [post_modified_gmt] => 2023-01-10 14:00:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [95] => WP_Post Object ( [ID] => 2890 [post_author] => 6 [post_date] => 2021-05-14 19:14:07 [post_date_gmt] => 2021-05-14 19:14:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:14:51 [post_modified_gmt] => 2023-01-10 11:14:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [96] => WP_Post Object ( [ID] => 2889 [post_author] => 6 [post_date] => 2021-05-14 19:09:07 [post_date_gmt] => 2021-05-14 19:09:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-10 12:43:57 [post_modified_gmt] => 2023-01-10 12:43:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2889 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [97] => WP_Post Object ( [ID] => 2885 [post_author] => 5 [post_date] => 2021-05-14 18:17:37 [post_date_gmt] => 2021-05-14 18:17:37 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:16:30 [post_modified_gmt] => 2023-01-10 13:16:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2885 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [98] => WP_Post Object ( [ID] => 1221 [post_author] => 6 [post_date] => 2020-05-22 20:09:53 [post_date_gmt] => 2020-05-22 20:09:53 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfpi3-template-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:12:53 [post_modified_gmt] => 2023-01-17 17:12:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [99] => WP_Post Object ( [ID] => 1205 [post_author] => 6 [post_date] => 2020-05-22 19:33:17 [post_date_gmt] => 2020-05-22 19:33:17 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-19 12:05:50 [post_modified_gmt] => 2023-01-19 12:05:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [100] => WP_Post Object ( [ID] => 1204 [post_author] => 6 [post_date] => 2020-05-22 19:31:46 [post_date_gmt] => 2020-05-22 19:31:46 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:26:09 [post_modified_gmt] => 2023-01-19 09:26:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [101] => WP_Post Object ( [ID] => 1203 [post_author] => 6 [post_date] => 2020-05-22 19:30:52 [post_date_gmt] => 2020-05-22 19:30:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-13 14:49:22 [post_modified_gmt] => 2023-01-13 14:49:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [102] => WP_Post Object ( [ID] => 1202 [post_author] => 6 [post_date] => 2020-05-22 19:28:49 [post_date_gmt] => 2020-05-22 19:28:49 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-13 14:47:56 [post_modified_gmt] => 2023-01-13 14:47:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [103] => WP_Post Object ( [ID] => 1159 [post_author] => 6 [post_date] => 2020-05-21 23:14:15 [post_date_gmt] => 2020-05-21 23:14:15 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:13:30 [post_modified_gmt] => 2023-01-17 17:13:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [104] => WP_Post Object ( [ID] => 996 [post_author] => 7 [post_date] => 2020-05-18 19:58:18 [post_date_gmt] => 2020-05-18 19:58:18 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:16:23 [post_modified_gmt] => 2023-01-17 17:16:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [105] => WP_Post Object ( [ID] => 5808 [post_author] => 5 [post_date] => 2022-10-04 10:04:03 [post_date_gmt] => 2022-10-04 10:04:03 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-04 10:04:03 [post_modified_gmt] => 2022-10-04 10:04:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [106] => WP_Post Object ( [ID] => 4661 [post_author] => 5 [post_date] => 2022-04-20 08:13:06 [post_date_gmt] => 2022-04-20 08:13:06 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:53:17 [post_modified_gmt] => 2022-10-03 13:53:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4661 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [107] => WP_Post Object ( [ID] => 4147 [post_author] => 5 [post_date] => 2022-04-18 12:53:51 [post_date_gmt] => 2022-04-18 12:53:51 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:24:43 [post_modified_gmt] => 2022-12-15 16:24:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4147 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [108] => WP_Post Object ( [ID] => 4148 [post_author] => 5 [post_date] => 2022-04-12 08:59:45 [post_date_gmt] => 2022-04-12 08:59:45 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-10-04 09:32:39 [post_modified_gmt] => 2022-10-04 09:32:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4148 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [109] => WP_Post Object ( [ID] => 4223 [post_author] => 5 [post_date] => 2022-03-04 09:43:58 [post_date_gmt] => 2022-03-04 09:43:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-05-31 18:00:18 [post_modified_gmt] => 2022-05-31 18:00:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4223 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [110] => WP_Post Object ( [ID] => 4222 [post_author] => 5 [post_date] => 2022-03-04 09:14:41 [post_date_gmt] => 2022-03-04 09:14:41 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:13:06 [post_modified_gmt] => 2022-10-12 11:13:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4222 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [111] => WP_Post Object ( [ID] => 4221 [post_author] => 5 [post_date] => 2022-03-04 09:05:29 [post_date_gmt] => 2022-03-04 09:05:29 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:36:15 [post_modified_gmt] => 2022-09-26 14:36:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [112] => WP_Post Object ( [ID] => 4220 [post_author] => 5 [post_date] => 2022-03-04 08:47:04 [post_date_gmt] => 2022-03-04 08:47:04 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-05-31 15:08:10 [post_modified_gmt] => 2022-05-31 15:08:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4220 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [113] => WP_Post Object ( [ID] => 4219 [post_author] => 5 [post_date] => 2022-03-04 08:02:15 [post_date_gmt] => 2022-03-04 08:02:15 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:55:41 [post_modified_gmt] => 2023-01-04 15:55:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4219 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [114] => WP_Post Object ( [ID] => 4218 [post_author] => 5 [post_date] => 2022-03-03 14:17:53 [post_date_gmt] => 2022-03-03 14:17:53 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:10:14 [post_modified_gmt] => 2023-01-04 15:10:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4218 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [115] => WP_Post Object ( [ID] => 4217 [post_author] => 5 [post_date] => 2022-03-03 13:59:58 [post_date_gmt] => 2022-03-03 13:59:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-05-31 17:56:43 [post_modified_gmt] => 2022-05-31 17:56:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4217 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [116] => WP_Post Object ( [ID] => 4216 [post_author] => 5 [post_date] => 2022-03-03 13:45:21 [post_date_gmt] => 2022-03-03 13:45:21 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-05-31 17:56:00 [post_modified_gmt] => 2022-05-31 17:56:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4216 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [117] => WP_Post Object ( [ID] => 4215 [post_author] => 5 [post_date] => 2022-03-03 13:31:56 [post_date_gmt] => 2022-03-03 13:31:56 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 10:41:55 [post_modified_gmt] => 2022-09-29 10:41:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4215 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [118] => WP_Post Object ( [ID] => 4214 [post_author] => 5 [post_date] => 2022-03-03 12:54:33 [post_date_gmt] => 2022-03-03 12:54:33 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:33:50 [post_modified_gmt] => 2022-12-15 16:33:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4214 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [119] => WP_Post Object ( [ID] => 4213 [post_author] => 5 [post_date] => 2022-03-03 10:54:01 [post_date_gmt] => 2022-03-03 10:54:01 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-05-31 15:05:32 [post_modified_gmt] => 2022-05-31 15:05:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4213 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [120] => WP_Post Object ( [ID] => 4212 [post_author] => 5 [post_date] => 2022-03-02 14:54:16 [post_date_gmt] => 2022-03-02 14:54:16 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:56:25 [post_modified_gmt] => 2022-10-12 12:56:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4212 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [121] => WP_Post Object ( [ID] => 4210 [post_author] => 5 [post_date] => 2022-03-02 13:14:31 [post_date_gmt] => 2022-03-02 13:14:31 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-07-13 12:03:49 [post_modified_gmt] => 2022-07-13 12:03:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4210 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [122] => WP_Post Object ( [ID] => 4209 [post_author] => 5 [post_date] => 2022-03-02 12:07:13 [post_date_gmt] => 2022-03-02 12:07:13 [post_content] => [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:16:54 [post_modified_gmt] => 2022-10-13 13:16:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4209 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [123] => WP_Post Object ( [ID] => 4161 [post_author] => 5 [post_date] => 2022-02-02 13:48:58 [post_date_gmt] => 2022-02-02 13:48:58 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-12-15 09:53:28 [post_modified_gmt] => 2022-12-15 09:53:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4161 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [124] => WP_Post Object ( [ID] => 4159 [post_author] => 5 [post_date] => 2022-02-02 13:10:48 [post_date_gmt] => 2022-02-02 13:10:48 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:15:11 [post_modified_gmt] => 2022-10-12 11:15:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4159 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [125] => WP_Post Object ( [ID] => 4158 [post_author] => 5 [post_date] => 2022-02-02 13:00:08 [post_date_gmt] => 2022-02-02 13:00:08 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-03 12:48:45 [post_modified_gmt] => 2023-01-03 12:48:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4158 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [126] => WP_Post Object ( [ID] => 4157 [post_author] => 5 [post_date] => 2022-02-02 12:54:56 [post_date_gmt] => 2022-02-02 12:54:56 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:13:37 [post_modified_gmt] => 2022-04-18 13:13:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [127] => WP_Post Object ( [ID] => 4156 [post_author] => 5 [post_date] => 2022-02-02 12:36:42 [post_date_gmt] => 2022-02-02 12:36:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:10:37 [post_modified_gmt] => 2023-01-04 15:10:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4156 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [128] => WP_Post Object ( [ID] => 4155 [post_author] => 5 [post_date] => 2022-02-02 12:19:16 [post_date_gmt] => 2022-02-02 12:19:16 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:12:26 [post_modified_gmt] => 2022-04-18 13:12:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4155 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [129] => WP_Post Object ( [ID] => 4154 [post_author] => 5 [post_date] => 2022-02-02 12:13:41 [post_date_gmt] => 2022-02-02 12:13:41 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-02-02 12:13:41 [post_modified_gmt] => 2022-02-02 12:13:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4154 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [130] => WP_Post Object ( [ID] => 4153 [post_author] => 5 [post_date] => 2022-02-02 12:10:13 [post_date_gmt] => 2022-02-02 12:10:13 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:28:28 [post_modified_gmt] => 2022-09-29 11:28:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4153 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [131] => WP_Post Object ( [ID] => 4152 [post_author] => 5 [post_date] => 2022-02-02 11:51:54 [post_date_gmt] => 2022-02-02 11:51:54 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:57:07 [post_modified_gmt] => 2022-09-26 14:57:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [132] => WP_Post Object ( [ID] => 4151 [post_author] => 5 [post_date] => 2022-02-02 11:39:24 [post_date_gmt] => 2022-02-02 11:39:24 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 13:00:22 [post_modified_gmt] => 2022-10-12 13:00:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [133] => WP_Post Object ( [ID] => 4150 [post_author] => 5 [post_date] => 2022-02-02 10:24:30 [post_date_gmt] => 2022-02-02 10:24:30 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:01:03 [post_modified_gmt] => 2022-04-18 13:01:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [134] => WP_Post Object ( [ID] => 4149 [post_author] => 5 [post_date] => 2022-02-02 10:15:42 [post_date_gmt] => 2022-02-02 10:15:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:35:19 [post_modified_gmt] => 2022-12-15 16:35:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4149 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [135] => WP_Post Object ( [ID] => 4146 [post_author] => 5 [post_date] => 2022-02-02 07:28:42 [post_date_gmt] => 2022-02-02 07:28:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:18:01 [post_modified_gmt] => 2022-10-13 13:18:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4146 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [136] => WP_Post Object ( [ID] => 3812 [post_author] => 5 [post_date] => 2021-09-10 12:44:57 [post_date_gmt] => 2021-09-10 12:44:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:53:37 [post_modified_gmt] => 2022-10-03 13:53:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3812 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [137] => WP_Post Object ( [ID] => 3810 [post_author] => 5 [post_date] => 2021-09-10 12:21:33 [post_date_gmt] => 2021-09-10 12:21:33 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:25:05 [post_modified_gmt] => 2022-10-12 11:25:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3810 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [138] => WP_Post Object ( [ID] => 3809 [post_author] => 5 [post_date] => 2021-09-10 12:11:12 [post_date_gmt] => 2021-09-10 12:11:12 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:54:22 [post_modified_gmt] => 2022-10-03 13:54:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3809 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [139] => WP_Post Object ( [ID] => 3808 [post_author] => 5 [post_date] => 2021-09-10 11:59:11 [post_date_gmt] => 2021-09-10 11:59:11 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-12-16 08:32:00 [post_modified_gmt] => 2022-12-16 08:32:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [140] => WP_Post Object ( [ID] => 3807 [post_author] => 5 [post_date] => 2021-09-10 11:55:25 [post_date_gmt] => 2021-09-10 11:55:25 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-12-15 15:01:53 [post_modified_gmt] => 2022-12-15 15:01:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [141] => WP_Post Object ( [ID] => 3806 [post_author] => 5 [post_date] => 2021-09-10 11:47:18 [post_date_gmt] => 2021-09-10 11:47:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:55:26 [post_modified_gmt] => 2022-10-03 13:55:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [142] => WP_Post Object ( [ID] => 3805 [post_author] => 5 [post_date] => 2021-09-10 11:33:53 [post_date_gmt] => 2021-09-10 11:33:53 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-03 13:02:35 [post_modified_gmt] => 2023-01-03 13:02:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [143] => WP_Post Object ( [ID] => 3804 [post_author] => 5 [post_date] => 2021-09-10 11:20:59 [post_date_gmt] => 2021-09-10 11:20:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-21 12:59:30 [post_modified_gmt] => 2023-03-21 12:59:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [144] => WP_Post Object ( [ID] => 3803 [post_author] => 5 [post_date] => 2021-09-10 10:54:42 [post_date_gmt] => 2021-09-10 10:54:42 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:57:32 [post_modified_gmt] => 2022-10-03 13:57:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3803 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [145] => WP_Post Object ( [ID] => 3802 [post_author] => 5 [post_date] => 2021-09-10 10:45:57 [post_date_gmt] => 2021-09-10 10:45:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:58:08 [post_modified_gmt] => 2022-10-03 13:58:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [146] => WP_Post Object ( [ID] => 3801 [post_author] => 5 [post_date] => 2021-09-10 10:36:30 [post_date_gmt] => 2021-09-10 10:36:30 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-12-14 15:47:05 [post_modified_gmt] => 2022-12-14 15:47:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3801 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [147] => WP_Post Object ( [ID] => 3800 [post_author] => 5 [post_date] => 2021-09-10 10:25:59 [post_date_gmt] => 2021-09-10 10:25:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:58:45 [post_modified_gmt] => 2022-10-03 13:58:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [148] => WP_Post Object ( [ID] => 3799 [post_author] => 5 [post_date] => 2021-09-10 10:07:18 [post_date_gmt] => 2021-09-10 10:07:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-16 12:45:40 [post_modified_gmt] => 2022-12-16 12:45:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3799 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [149] => WP_Post Object ( [ID] => 3798 [post_author] => 5 [post_date] => 2021-09-10 10:02:07 [post_date_gmt] => 2021-09-10 10:02:07 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:59:19 [post_modified_gmt] => 2022-10-03 13:59:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [150] => WP_Post Object ( [ID] => 3797 [post_author] => 5 [post_date] => 2021-09-10 09:54:44 [post_date_gmt] => 2021-09-10 09:54:44 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:59:36 [post_modified_gmt] => 2022-10-03 13:59:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3797 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [151] => WP_Post Object ( [ID] => 3796 [post_author] => 5 [post_date] => 2021-09-10 09:03:43 [post_date_gmt] => 2021-09-10 09:03:43 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-11-09 15:00:19 [post_modified_gmt] => 2022-11-09 15:00:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3796 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 152 [current_post] => -1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 8491 [post_author] => 5 [post_date] => 2023-01-19 11:34:54 [post_date_gmt] => 2023-01-19 11:34:54 [post_content] => [post_title] => CEPI CfP3i Vaccine Funding Agreement Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-vaccine-funding-agreement-template [to_ping] => [pinged] => [post_modified] => 2023-01-19 11:34:54 [post_modified_gmt] => 2023-01-19 11:34:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8491 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 152 [max_num_pages] => 0 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => 1 [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => 1 [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => 1 [query_vars_hash:WP_Query:private] => d1a97f870fa3d3de84ebbf4dd1ae72e2 [query_vars_changed:WP_Query:private] => 1 [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => Array ( [0] => about [1] => an [2] => are [3] => as [4] => at [5] => be [6] => by [7] => com [8] => for [9] => from [10] => how [11] => in [12] => is [13] => it [14] => of [15] => on [16] => or [17] => that [18] => the [19] => this [20] => to [21] => was [22] => what [23] => when [24] => where [25] => who [26] => will [27] => with [28] => www ) [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) ) [provisions] => Array ( [0] => WP_Post Object ( [ID] => 8491 [post_author] => 5 [post_date] => 2023-01-19 11:34:54 [post_date_gmt] => 2023-01-19 11:34:54 [post_content] => [post_title] => CEPI CfP3i Vaccine Funding Agreement Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-vaccine-funding-agreement-template [to_ping] => [pinged] => [post_modified] => 2023-01-19 11:34:54 [post_modified_gmt] => 2023-01-19 11:34:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8491 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 8490 [post_author] => 5 [post_date] => 2023-01-19 11:11:46 [post_date_gmt] => 2023-01-19 11:11:46 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-01-19 11:11:46 [post_modified_gmt] => 2023-01-19 11:11:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8490 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 8489 [post_author] => 5 [post_date] => 2023-01-19 10:44:52 [post_date_gmt] => 2023-01-19 10:44:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:44:52 [post_modified_gmt] => 2023-01-19 10:44:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8489 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 8488 [post_author] => 5 [post_date] => 2023-01-19 10:15:15 [post_date_gmt] => 2023-01-19 10:15:15 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:15:15 [post_modified_gmt] => 2023-01-19 10:15:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8488 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 8487 [post_author] => 5 [post_date] => 2023-01-19 09:59:54 [post_date_gmt] => 2023-01-19 09:59:54 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:59:54 [post_modified_gmt] => 2023-01-19 09:59:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8487 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 8486 [post_author] => 5 [post_date] => 2023-01-19 09:46:36 [post_date_gmt] => 2023-01-19 09:46:36 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:46:36 [post_modified_gmt] => 2023-01-19 09:46:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8486 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [6] => WP_Post Object ( [ID] => 8485 [post_author] => 5 [post_date] => 2023-01-19 09:39:38 [post_date_gmt] => 2023-01-19 09:39:38 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:39:38 [post_modified_gmt] => 2023-01-19 09:39:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8485 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [7] => WP_Post Object ( [ID] => 8484 [post_author] => 5 [post_date] => 2023-01-19 09:17:50 [post_date_gmt] => 2023-01-19 09:17:50 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:17:50 [post_modified_gmt] => 2023-01-19 09:17:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8484 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [8] => WP_Post Object ( [ID] => 8482 [post_author] => 5 [post_date] => 2023-01-18 16:32:52 [post_date_gmt] => 2023-01-18 16:32:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-18 16:32:52 [post_modified_gmt] => 2023-01-18 16:32:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8482 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [9] => WP_Post Object ( [ID] => 8481 [post_author] => 5 [post_date] => 2023-01-18 15:49:38 [post_date_gmt] => 2023-01-18 15:49:38 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-19 12:07:24 [post_modified_gmt] => 2023-01-19 12:07:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8481 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [10] => WP_Post Object ( [ID] => 8480 [post_author] => 5 [post_date] => 2023-01-17 17:53:00 [post_date_gmt] => 2023-01-17 17:53:00 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:53:00 [post_modified_gmt] => 2023-01-17 17:53:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8480 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [11] => WP_Post Object ( [ID] => 8479 [post_author] => 5 [post_date] => 2023-01-17 17:35:45 [post_date_gmt] => 2023-01-17 17:35:45 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:35:45 [post_modified_gmt] => 2023-01-17 17:35:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8479 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [12] => WP_Post Object ( [ID] => 8469 [post_author] => 5 [post_date] => 2023-01-13 13:35:47 [post_date_gmt] => 2023-01-13 13:35:47 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19 [to_ping] => [pinged] => [post_modified] => 2023-01-13 13:35:47 [post_modified_gmt] => 2023-01-13 13:35:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8469 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [13] => WP_Post Object ( [ID] => 8468 [post_author] => 5 [post_date] => 2023-01-11 14:35:38 [post_date_gmt] => 2023-01-11 14:35:38 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-11 14:54:13 [post_modified_gmt] => 2023-01-11 14:54:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8468 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [14] => WP_Post Object ( [ID] => 8467 [post_author] => 5 [post_date] => 2023-01-11 14:29:13 [post_date_gmt] => 2023-01-11 14:29:13 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-11 14:36:41 [post_modified_gmt] => 2023-01-11 14:36:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8467 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [15] => WP_Post Object ( [ID] => 8462 [post_author] => 5 [post_date] => 2023-01-10 12:12:52 [post_date_gmt] => 2023-01-10 12:12:52 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-10 12:21:16 [post_modified_gmt] => 2023-01-10 12:21:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8462 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [16] => WP_Post Object ( [ID] => 8461 [post_author] => 5 [post_date] => 2023-01-10 09:08:41 [post_date_gmt] => 2023-01-10 09:08:41 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 09:17:07 [post_modified_gmt] => 2023-01-10 09:17:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8461 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [17] => WP_Post Object ( [ID] => 8314 [post_author] => 5 [post_date] => 2022-12-13 11:46:36 [post_date_gmt] => 2022-12-13 11:46:36 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-12-13 11:46:36 [post_modified_gmt] => 2022-12-13 11:46:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8314 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [18] => WP_Post Object ( [ID] => 8313 [post_author] => 5 [post_date] => 2022-12-13 10:48:56 [post_date_gmt] => 2022-12-13 10:48:56 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-12-13 10:48:56 [post_modified_gmt] => 2022-12-13 10:48:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8313 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [19] => WP_Post Object ( [ID] => 8312 [post_author] => 5 [post_date] => 2022-12-13 10:35:08 [post_date_gmt] => 2022-12-13 10:35:08 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-12-13 10:35:08 [post_modified_gmt] => 2022-12-13 10:35:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8312 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [20] => WP_Post Object ( [ID] => 8311 [post_author] => 5 [post_date] => 2022-12-13 10:09:44 [post_date_gmt] => 2022-12-13 10:09:44 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-12-13 10:09:44 [post_modified_gmt] => 2022-12-13 10:09:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8311 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [21] => WP_Post Object ( [ID] => 8192 [post_author] => 5 [post_date] => 2022-12-13 09:04:26 [post_date_gmt] => 2022-12-13 09:04:26 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-12-13 09:05:52 [post_modified_gmt] => 2022-12-13 09:05:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8192 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [22] => WP_Post Object ( [ID] => 8191 [post_author] => 5 [post_date] => 2022-12-12 16:19:19 [post_date_gmt] => 2022-12-12 16:19:19 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:55:07 [post_modified_gmt] => 2022-12-13 12:55:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8191 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [23] => WP_Post Object ( [ID] => 8190 [post_author] => 5 [post_date] => 2022-12-12 15:29:46 [post_date_gmt] => 2022-12-12 15:29:46 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:05:30 [post_modified_gmt] => 2022-12-14 13:05:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8190 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [24] => WP_Post Object ( [ID] => 8157 [post_author] => 5 [post_date] => 2022-12-12 15:23:50 [post_date_gmt] => 2022-12-12 15:23:50 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:06:57 [post_modified_gmt] => 2023-03-28 14:06:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [25] => WP_Post Object ( [ID] => 8152 [post_author] => 5 [post_date] => 2022-12-12 12:04:21 [post_date_gmt] => 2022-12-12 12:04:21 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:56:37 [post_modified_gmt] => 2022-12-13 12:56:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [26] => WP_Post Object ( [ID] => 8151 [post_author] => 5 [post_date] => 2022-12-12 11:56:08 [post_date_gmt] => 2022-12-12 11:56:08 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-12-13 13:04:22 [post_modified_gmt] => 2022-12-13 13:04:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [27] => WP_Post Object ( [ID] => 8150 [post_author] => 5 [post_date] => 2022-12-12 11:21:26 [post_date_gmt] => 2022-12-12 11:21:26 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-12-12 11:48:09 [post_modified_gmt] => 2022-12-12 11:48:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [28] => WP_Post Object ( [ID] => 8143 [post_author] => 5 [post_date] => 2022-12-12 11:10:19 [post_date_gmt] => 2022-12-12 11:10:19 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-12-12 11:10:19 [post_modified_gmt] => 2022-12-12 11:10:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8143 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [29] => WP_Post Object ( [ID] => 8142 [post_author] => 5 [post_date] => 2022-12-12 10:40:31 [post_date_gmt] => 2022-12-12 10:40:31 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:57:50 [post_modified_gmt] => 2022-12-13 12:57:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8142 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [30] => WP_Post Object ( [ID] => 8131 [post_author] => 5 [post_date] => 2022-12-12 09:57:36 [post_date_gmt] => 2022-12-12 09:57:36 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:49:55 [post_modified_gmt] => 2022-12-13 12:49:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [31] => WP_Post Object ( [ID] => 8130 [post_author] => 5 [post_date] => 2022-12-12 09:34:49 [post_date_gmt] => 2022-12-12 09:34:49 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:51:49 [post_modified_gmt] => 2022-12-13 12:51:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [32] => WP_Post Object ( [ID] => 8129 [post_author] => 5 [post_date] => 2022-12-12 08:55:53 [post_date_gmt] => 2022-12-12 08:55:53 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:45:31 [post_modified_gmt] => 2022-12-13 12:45:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [33] => WP_Post Object ( [ID] => 8051 [post_author] => 5 [post_date] => 2022-12-12 08:39:19 [post_date_gmt] => 2022-12-12 08:39:19 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:54:45 [post_modified_gmt] => 2023-01-10 13:54:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8051 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [34] => WP_Post Object ( [ID] => 5808 [post_author] => 5 [post_date] => 2022-10-04 10:04:03 [post_date_gmt] => 2022-10-04 10:04:03 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-04 10:04:03 [post_modified_gmt] => 2022-10-04 10:04:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [35] => WP_Post Object ( [ID] => 5782 [post_author] => 5 [post_date] => 2022-09-16 07:28:56 [post_date_gmt] => 2022-09-16 07:28:56 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:52:08 [post_modified_gmt] => 2023-01-10 13:52:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5782 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [36] => WP_Post Object ( [ID] => 5653 [post_author] => 5 [post_date] => 2022-08-25 12:56:30 [post_date_gmt] => 2022-08-25 12:56:30 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 12:24:08 [post_modified_gmt] => 2023-01-10 12:24:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5653 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [37] => WP_Post Object ( [ID] => 5652 [post_author] => 5 [post_date] => 2022-08-25 12:26:53 [post_date_gmt] => 2022-08-25 12:26:53 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:46:10 [post_modified_gmt] => 2023-01-10 11:46:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5652 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [38] => WP_Post Object ( [ID] => 5427 [post_author] => 5 [post_date] => 2022-07-22 15:20:29 [post_date_gmt] => 2022-07-22 15:20:29 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-05 13:37:17 [post_modified_gmt] => 2023-01-05 13:37:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5427 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [39] => WP_Post Object ( [ID] => 4661 [post_author] => 5 [post_date] => 2022-04-20 08:13:06 [post_date_gmt] => 2022-04-20 08:13:06 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:53:17 [post_modified_gmt] => 2022-10-03 13:53:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4661 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [40] => WP_Post Object ( [ID] => 4147 [post_author] => 5 [post_date] => 2022-04-18 12:53:51 [post_date_gmt] => 2022-04-18 12:53:51 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:24:43 [post_modified_gmt] => 2022-12-15 16:24:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4147 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [41] => WP_Post Object ( [ID] => 4148 [post_author] => 5 [post_date] => 2022-04-12 08:59:45 [post_date_gmt] => 2022-04-12 08:59:45 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-10-04 09:32:39 [post_modified_gmt] => 2022-10-04 09:32:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4148 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [42] => WP_Post Object ( [ID] => 4580 [post_author] => 5 [post_date] => 2022-03-31 14:34:38 [post_date_gmt] => 2022-03-31 14:34:38 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:02:54 [post_modified_gmt] => 2023-01-05 14:02:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4580 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [43] => WP_Post Object ( [ID] => 4223 [post_author] => 5 [post_date] => 2022-03-04 09:43:58 [post_date_gmt] => 2022-03-04 09:43:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-05-31 18:00:18 [post_modified_gmt] => 2022-05-31 18:00:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4223 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [44] => WP_Post Object ( [ID] => 4222 [post_author] => 5 [post_date] => 2022-03-04 09:14:41 [post_date_gmt] => 2022-03-04 09:14:41 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:13:06 [post_modified_gmt] => 2022-10-12 11:13:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4222 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [45] => WP_Post Object ( [ID] => 4221 [post_author] => 5 [post_date] => 2022-03-04 09:05:29 [post_date_gmt] => 2022-03-04 09:05:29 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:36:15 [post_modified_gmt] => 2022-09-26 14:36:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [46] => WP_Post Object ( [ID] => 4220 [post_author] => 5 [post_date] => 2022-03-04 08:47:04 [post_date_gmt] => 2022-03-04 08:47:04 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-05-31 15:08:10 [post_modified_gmt] => 2022-05-31 15:08:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4220 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [47] => WP_Post Object ( [ID] => 4219 [post_author] => 5 [post_date] => 2022-03-04 08:02:15 [post_date_gmt] => 2022-03-04 08:02:15 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:55:41 [post_modified_gmt] => 2023-01-04 15:55:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4219 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [48] => WP_Post Object ( [ID] => 4218 [post_author] => 5 [post_date] => 2022-03-03 14:17:53 [post_date_gmt] => 2022-03-03 14:17:53 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:10:14 [post_modified_gmt] => 2023-01-04 15:10:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4218 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [49] => WP_Post Object ( [ID] => 4217 [post_author] => 5 [post_date] => 2022-03-03 13:59:58 [post_date_gmt] => 2022-03-03 13:59:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-05-31 17:56:43 [post_modified_gmt] => 2022-05-31 17:56:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4217 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [50] => WP_Post Object ( [ID] => 4216 [post_author] => 5 [post_date] => 2022-03-03 13:45:21 [post_date_gmt] => 2022-03-03 13:45:21 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-05-31 17:56:00 [post_modified_gmt] => 2022-05-31 17:56:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4216 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [51] => WP_Post Object ( [ID] => 4215 [post_author] => 5 [post_date] => 2022-03-03 13:31:56 [post_date_gmt] => 2022-03-03 13:31:56 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 10:41:55 [post_modified_gmt] => 2022-09-29 10:41:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4215 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [52] => WP_Post Object ( [ID] => 4214 [post_author] => 5 [post_date] => 2022-03-03 12:54:33 [post_date_gmt] => 2022-03-03 12:54:33 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:33:50 [post_modified_gmt] => 2022-12-15 16:33:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4214 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [53] => WP_Post Object ( [ID] => 4213 [post_author] => 5 [post_date] => 2022-03-03 10:54:01 [post_date_gmt] => 2022-03-03 10:54:01 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-05-31 15:05:32 [post_modified_gmt] => 2022-05-31 15:05:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4213 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [54] => WP_Post Object ( [ID] => 4212 [post_author] => 5 [post_date] => 2022-03-02 14:54:16 [post_date_gmt] => 2022-03-02 14:54:16 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:56:25 [post_modified_gmt] => 2022-10-12 12:56:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4212 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [55] => WP_Post Object ( [ID] => 4210 [post_author] => 5 [post_date] => 2022-03-02 13:14:31 [post_date_gmt] => 2022-03-02 13:14:31 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-07-13 12:03:49 [post_modified_gmt] => 2022-07-13 12:03:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4210 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [56] => WP_Post Object ( [ID] => 4209 [post_author] => 5 [post_date] => 2022-03-02 12:07:13 [post_date_gmt] => 2022-03-02 12:07:13 [post_content] => [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:16:54 [post_modified_gmt] => 2022-10-13 13:16:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4209 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [57] => WP_Post Object ( [ID] => 4205 [post_author] => 5 [post_date] => 2022-02-28 15:24:19 [post_date_gmt] => 2022-02-28 15:24:19 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:59:13 [post_modified_gmt] => 2022-10-12 12:59:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4205 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [58] => WP_Post Object ( [ID] => 4204 [post_author] => 5 [post_date] => 2022-02-28 14:53:11 [post_date_gmt] => 2022-02-28 14:53:11 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:07:32 [post_modified_gmt] => 2022-12-14 13:07:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4204 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [59] => WP_Post Object ( [ID] => 4201 [post_author] => 5 [post_date] => 2022-02-28 13:33:22 [post_date_gmt] => 2022-02-28 13:33:22 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:13:57 [post_modified_gmt] => 2023-01-10 13:13:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4201 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [60] => WP_Post Object ( [ID] => 4200 [post_author] => 5 [post_date] => 2022-02-28 13:13:29 [post_date_gmt] => 2022-02-28 13:13:29 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:13:52 [post_modified_gmt] => 2022-10-12 11:13:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4200 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [61] => WP_Post Object ( [ID] => 4161 [post_author] => 5 [post_date] => 2022-02-02 13:48:58 [post_date_gmt] => 2022-02-02 13:48:58 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-12-15 09:53:28 [post_modified_gmt] => 2022-12-15 09:53:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4161 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [62] => WP_Post Object ( [ID] => 4159 [post_author] => 5 [post_date] => 2022-02-02 13:10:48 [post_date_gmt] => 2022-02-02 13:10:48 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:15:11 [post_modified_gmt] => 2022-10-12 11:15:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4159 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [63] => WP_Post Object ( [ID] => 4158 [post_author] => 5 [post_date] => 2022-02-02 13:00:08 [post_date_gmt] => 2022-02-02 13:00:08 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-03 12:48:45 [post_modified_gmt] => 2023-01-03 12:48:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4158 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [64] => WP_Post Object ( [ID] => 4157 [post_author] => 5 [post_date] => 2022-02-02 12:54:56 [post_date_gmt] => 2022-02-02 12:54:56 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:13:37 [post_modified_gmt] => 2022-04-18 13:13:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [65] => WP_Post Object ( [ID] => 4156 [post_author] => 5 [post_date] => 2022-02-02 12:36:42 [post_date_gmt] => 2022-02-02 12:36:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:10:37 [post_modified_gmt] => 2023-01-04 15:10:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4156 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [66] => WP_Post Object ( [ID] => 4155 [post_author] => 5 [post_date] => 2022-02-02 12:19:16 [post_date_gmt] => 2022-02-02 12:19:16 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:12:26 [post_modified_gmt] => 2022-04-18 13:12:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4155 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [67] => WP_Post Object ( [ID] => 4154 [post_author] => 5 [post_date] => 2022-02-02 12:13:41 [post_date_gmt] => 2022-02-02 12:13:41 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-02-02 12:13:41 [post_modified_gmt] => 2022-02-02 12:13:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4154 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [68] => WP_Post Object ( [ID] => 4153 [post_author] => 5 [post_date] => 2022-02-02 12:10:13 [post_date_gmt] => 2022-02-02 12:10:13 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:28:28 [post_modified_gmt] => 2022-09-29 11:28:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4153 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [69] => WP_Post Object ( [ID] => 4152 [post_author] => 5 [post_date] => 2022-02-02 11:51:54 [post_date_gmt] => 2022-02-02 11:51:54 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:57:07 [post_modified_gmt] => 2022-09-26 14:57:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [70] => WP_Post Object ( [ID] => 4151 [post_author] => 5 [post_date] => 2022-02-02 11:39:24 [post_date_gmt] => 2022-02-02 11:39:24 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 13:00:22 [post_modified_gmt] => 2022-10-12 13:00:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [71] => WP_Post Object ( [ID] => 4150 [post_author] => 5 [post_date] => 2022-02-02 10:24:30 [post_date_gmt] => 2022-02-02 10:24:30 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:01:03 [post_modified_gmt] => 2022-04-18 13:01:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [72] => WP_Post Object ( [ID] => 4149 [post_author] => 5 [post_date] => 2022-02-02 10:15:42 [post_date_gmt] => 2022-02-02 10:15:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:35:19 [post_modified_gmt] => 2022-12-15 16:35:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4149 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [73] => WP_Post Object ( [ID] => 4146 [post_author] => 5 [post_date] => 2022-02-02 07:28:42 [post_date_gmt] => 2022-02-02 07:28:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:18:01 [post_modified_gmt] => 2022-10-13 13:18:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4146 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [74] => WP_Post Object ( [ID] => 4141 [post_author] => 5 [post_date] => 2022-01-31 14:31:23 [post_date_gmt] => 2022-01-31 14:31:23 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:40:20 [post_modified_gmt] => 2023-01-10 10:40:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4141 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [75] => WP_Post Object ( [ID] => 4140 [post_author] => 5 [post_date] => 2022-01-31 14:22:03 [post_date_gmt] => 2022-01-31 14:22:03 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:54:15 [post_modified_gmt] => 2023-01-10 10:54:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4140 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [76] => WP_Post Object ( [ID] => 4139 [post_author] => 5 [post_date] => 2022-01-31 14:18:32 [post_date_gmt] => 2022-01-31 14:18:32 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:58:00 [post_modified_gmt] => 2023-01-10 10:58:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4139 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [77] => WP_Post Object ( [ID] => 4138 [post_author] => 5 [post_date] => 2022-01-31 14:09:33 [post_date_gmt] => 2022-01-31 14:09:33 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:59:39 [post_modified_gmt] => 2023-01-10 10:59:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4138 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [78] => WP_Post Object ( [ID] => 4137 [post_author] => 5 [post_date] => 2022-01-31 13:53:37 [post_date_gmt] => 2022-01-31 13:53:37 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:02:20 [post_modified_gmt] => 2023-01-10 11:02:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4137 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [79] => WP_Post Object ( [ID] => 4136 [post_author] => 5 [post_date] => 2022-01-31 13:42:47 [post_date_gmt] => 2022-01-31 13:42:47 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:01:51 [post_modified_gmt] => 2023-01-10 11:01:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4136 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [80] => WP_Post Object ( [ID] => 4135 [post_author] => 5 [post_date] => 2022-01-31 13:25:08 [post_date_gmt] => 2022-01-31 13:25:08 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:59:11 [post_modified_gmt] => 2023-01-10 10:59:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4135 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [81] => WP_Post Object ( [ID] => 4134 [post_author] => 5 [post_date] => 2022-01-31 12:56:28 [post_date_gmt] => 2022-01-31 12:56:28 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:58:24 [post_modified_gmt] => 2023-01-10 10:58:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4134 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [82] => WP_Post Object ( [ID] => 4133 [post_author] => 5 [post_date] => 2022-01-31 12:22:56 [post_date_gmt] => 2022-01-31 12:22:56 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:56:11 [post_modified_gmt] => 2023-01-10 10:56:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4133 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [83] => WP_Post Object ( [ID] => 4131 [post_author] => 5 [post_date] => 2022-01-29 16:21:19 [post_date_gmt] => 2022-01-29 16:21:19 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:56:47 [post_modified_gmt] => 2023-01-10 10:56:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [84] => WP_Post Object ( [ID] => 4130 [post_author] => 5 [post_date] => 2022-01-29 15:34:50 [post_date_gmt] => 2022-01-29 15:34:50 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:57:20 [post_modified_gmt] => 2023-01-10 10:57:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [85] => WP_Post Object ( [ID] => 4129 [post_author] => 5 [post_date] => 2022-01-28 14:43:06 [post_date_gmt] => 2022-01-28 14:43:06 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:53:31 [post_modified_gmt] => 2023-01-10 10:53:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [86] => WP_Post Object ( [ID] => 4128 [post_author] => 5 [post_date] => 2022-01-28 13:38:44 [post_date_gmt] => 2022-01-28 13:38:44 [post_content] => [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:07:15 [post_modified_gmt] => 2023-01-10 11:07:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4128 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [87] => WP_Post Object ( [ID] => 3812 [post_author] => 5 [post_date] => 2021-09-10 12:44:57 [post_date_gmt] => 2021-09-10 12:44:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:53:37 [post_modified_gmt] => 2022-10-03 13:53:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3812 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [88] => WP_Post Object ( [ID] => 3810 [post_author] => 5 [post_date] => 2021-09-10 12:21:33 [post_date_gmt] => 2021-09-10 12:21:33 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:25:05 [post_modified_gmt] => 2022-10-12 11:25:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3810 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [89] => WP_Post Object ( [ID] => 3809 [post_author] => 5 [post_date] => 2021-09-10 12:11:12 [post_date_gmt] => 2021-09-10 12:11:12 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:54:22 [post_modified_gmt] => 2022-10-03 13:54:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3809 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [90] => WP_Post Object ( [ID] => 3808 [post_author] => 5 [post_date] => 2021-09-10 11:59:11 [post_date_gmt] => 2021-09-10 11:59:11 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-12-16 08:32:00 [post_modified_gmt] => 2022-12-16 08:32:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [91] => WP_Post Object ( [ID] => 3807 [post_author] => 5 [post_date] => 2021-09-10 11:55:25 [post_date_gmt] => 2021-09-10 11:55:25 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-12-15 15:01:53 [post_modified_gmt] => 2022-12-15 15:01:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [92] => WP_Post Object ( [ID] => 3806 [post_author] => 5 [post_date] => 2021-09-10 11:47:18 [post_date_gmt] => 2021-09-10 11:47:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:55:26 [post_modified_gmt] => 2022-10-03 13:55:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [93] => WP_Post Object ( [ID] => 3805 [post_author] => 5 [post_date] => 2021-09-10 11:33:53 [post_date_gmt] => 2021-09-10 11:33:53 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-03 13:02:35 [post_modified_gmt] => 2023-01-03 13:02:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [94] => WP_Post Object ( [ID] => 3804 [post_author] => 5 [post_date] => 2021-09-10 11:20:59 [post_date_gmt] => 2021-09-10 11:20:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-21 12:59:30 [post_modified_gmt] => 2023-03-21 12:59:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [95] => WP_Post Object ( [ID] => 3803 [post_author] => 5 [post_date] => 2021-09-10 10:54:42 [post_date_gmt] => 2021-09-10 10:54:42 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:57:32 [post_modified_gmt] => 2022-10-03 13:57:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3803 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [96] => WP_Post Object ( [ID] => 3802 [post_author] => 5 [post_date] => 2021-09-10 10:45:57 [post_date_gmt] => 2021-09-10 10:45:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:58:08 [post_modified_gmt] => 2022-10-03 13:58:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [97] => WP_Post Object ( [ID] => 3801 [post_author] => 5 [post_date] => 2021-09-10 10:36:30 [post_date_gmt] => 2021-09-10 10:36:30 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-12-14 15:47:05 [post_modified_gmt] => 2022-12-14 15:47:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3801 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [98] => WP_Post Object ( [ID] => 3800 [post_author] => 5 [post_date] => 2021-09-10 10:25:59 [post_date_gmt] => 2021-09-10 10:25:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:58:45 [post_modified_gmt] => 2022-10-03 13:58:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [99] => WP_Post Object ( [ID] => 3799 [post_author] => 5 [post_date] => 2021-09-10 10:07:18 [post_date_gmt] => 2021-09-10 10:07:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-16 12:45:40 [post_modified_gmt] => 2022-12-16 12:45:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3799 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [100] => WP_Post Object ( [ID] => 3798 [post_author] => 5 [post_date] => 2021-09-10 10:02:07 [post_date_gmt] => 2021-09-10 10:02:07 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:59:19 [post_modified_gmt] => 2022-10-03 13:59:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [101] => WP_Post Object ( [ID] => 3797 [post_author] => 5 [post_date] => 2021-09-10 09:54:44 [post_date_gmt] => 2021-09-10 09:54:44 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:59:36 [post_modified_gmt] => 2022-10-03 13:59:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3797 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [102] => WP_Post Object ( [ID] => 3796 [post_author] => 5 [post_date] => 2021-09-10 09:03:43 [post_date_gmt] => 2021-09-10 09:03:43 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-11-09 15:00:19 [post_modified_gmt] => 2022-11-09 15:00:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3796 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [103] => WP_Post Object ( [ID] => 3757 [post_author] => 5 [post_date] => 2021-08-25 08:42:34 [post_date_gmt] => 2021-08-25 08:42:34 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:47:08 [post_modified_gmt] => 2023-01-11 15:47:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3757 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [104] => WP_Post Object ( [ID] => 3756 [post_author] => 5 [post_date] => 2021-08-25 08:10:37 [post_date_gmt] => 2021-08-25 08:10:37 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:39:31 [post_modified_gmt] => 2023-01-11 15:39:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3756 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [105] => WP_Post Object ( [ID] => 3755 [post_author] => 5 [post_date] => 2021-08-25 07:55:51 [post_date_gmt] => 2021-08-25 07:55:51 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:24:11 [post_modified_gmt] => 2023-01-19 09:24:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3755 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [106] => WP_Post Object ( [ID] => 3754 [post_author] => 5 [post_date] => 2021-08-24 13:43:37 [post_date_gmt] => 2021-08-24 13:43:37 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:59:38 [post_modified_gmt] => 2023-01-12 13:59:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3754 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [107] => WP_Post Object ( [ID] => 3753 [post_author] => 5 [post_date] => 2021-08-24 13:14:41 [post_date_gmt] => 2021-08-24 13:14:41 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:13:40 [post_modified_gmt] => 2023-01-19 10:13:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3753 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [108] => WP_Post Object ( [ID] => 3751 [post_author] => 5 [post_date] => 2021-08-24 12:54:56 [post_date_gmt] => 2021-08-24 12:54:56 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:20:29 [post_modified_gmt] => 2023-01-12 13:20:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3751 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [109] => WP_Post Object ( [ID] => 3749 [post_author] => 5 [post_date] => 2021-08-24 12:40:53 [post_date_gmt] => 2021-08-24 12:40:53 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:33:44 [post_modified_gmt] => 2023-01-12 13:33:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3749 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [110] => WP_Post Object ( [ID] => 3748 [post_author] => 5 [post_date] => 2021-08-24 12:31:07 [post_date_gmt] => 2021-08-24 12:31:07 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-11 14:17:38 [post_modified_gmt] => 2023-01-11 14:17:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3748 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [111] => WP_Post Object ( [ID] => 3747 [post_author] => 5 [post_date] => 2021-08-24 11:12:07 [post_date_gmt] => 2021-08-24 11:12:07 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:28:33 [post_modified_gmt] => 2023-01-11 15:28:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3747 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [112] => WP_Post Object ( [ID] => 3746 [post_author] => 5 [post_date] => 2021-08-24 10:45:05 [post_date_gmt] => 2021-08-24 10:45:05 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:55:51 [post_modified_gmt] => 2023-01-11 15:55:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3746 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [113] => WP_Post Object ( [ID] => 3744 [post_author] => 5 [post_date] => 2021-08-24 10:32:54 [post_date_gmt] => 2021-08-24 10:32:54 [post_content] => [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:06:21 [post_modified_gmt] => 2023-03-28 14:06:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3744 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [114] => WP_Post Object ( [ID] => 3743 [post_author] => 5 [post_date] => 2021-08-24 10:19:00 [post_date_gmt] => 2021-08-24 10:19:00 [post_content] => [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:53:13 [post_modified_gmt] => 2023-01-11 15:53:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3743 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [115] => WP_Post Object ( [ID] => 3736 [post_author] => 5 [post_date] => 2021-08-24 07:47:09 [post_date_gmt] => 2021-08-24 07:47:09 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-13 14:46:43 [post_modified_gmt] => 2023-01-13 14:46:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3736 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [116] => WP_Post Object ( [ID] => 3726 [post_author] => 5 [post_date] => 2021-08-23 16:13:39 [post_date_gmt] => 2021-08-23 16:13:39 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:23:48 [post_modified_gmt] => 2023-01-11 15:23:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3726 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [117] => WP_Post Object ( [ID] => 3725 [post_author] => 5 [post_date] => 2021-08-23 13:56:41 [post_date_gmt] => 2021-08-23 13:56:41 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:50:35 [post_modified_gmt] => 2023-01-11 15:50:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3725 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [118] => WP_Post Object ( [ID] => 3724 [post_author] => 5 [post_date] => 2021-08-23 13:11:07 [post_date_gmt] => 2021-08-23 13:11:07 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:27:12 [post_modified_gmt] => 2023-01-11 15:27:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3724 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [119] => WP_Post Object ( [ID] => 3722 [post_author] => 5 [post_date] => 2021-08-23 12:12:50 [post_date_gmt] => 2021-08-23 12:12:50 [post_content] => [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-11 15:42:28 [post_modified_gmt] => 2023-01-11 15:42:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3722 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [120] => WP_Post Object ( [ID] => 3493 [post_author] => 5 [post_date] => 2021-08-10 11:15:39 [post_date_gmt] => 2021-08-10 11:15:39 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 14:19:31 [post_modified_gmt] => 2023-01-10 14:19:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3493 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [121] => WP_Post Object ( [ID] => 3344 [post_author] => 6 [post_date] => 2021-06-30 13:02:36 [post_date_gmt] => 2021-06-30 13:02:36 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-22 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:29:20 [post_modified_gmt] => 2023-01-05 15:29:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3344 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [122] => WP_Post Object ( [ID] => 3343 [post_author] => 6 [post_date] => 2021-06-30 12:57:07 [post_date_gmt] => 2021-06-30 12:57:07 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-21 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:31:21 [post_modified_gmt] => 2023-01-05 15:31:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3343 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [123] => WP_Post Object ( [ID] => 3342 [post_author] => 6 [post_date] => 2021-06-30 12:50:17 [post_date_gmt] => 2021-06-30 12:50:17 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-20 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:05:20 [post_modified_gmt] => 2023-01-05 15:05:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3342 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [124] => WP_Post Object ( [ID] => 3341 [post_author] => 6 [post_date] => 2021-06-30 12:44:43 [post_date_gmt] => 2021-06-30 12:44:43 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-19 [to_ping] => [pinged] => [post_modified] => 2023-01-05 15:04:39 [post_modified_gmt] => 2023-01-05 15:04:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3341 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [125] => WP_Post Object ( [ID] => 3339 [post_author] => 6 [post_date] => 2021-06-30 12:37:28 [post_date_gmt] => 2021-06-30 12:37:28 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-01-12 13:27:08 [post_modified_gmt] => 2023-01-12 13:27:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3339 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [126] => WP_Post Object ( [ID] => 3338 [post_author] => 6 [post_date] => 2021-06-30 12:27:08 [post_date_gmt] => 2021-06-30 12:27:08 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:23:29 [post_modified_gmt] => 2023-01-05 14:23:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3338 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [127] => WP_Post Object ( [ID] => 3336 [post_author] => 6 [post_date] => 2021-06-30 12:18:57 [post_date_gmt] => 2021-06-30 12:18:57 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:57:18 [post_modified_gmt] => 2023-01-05 14:57:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3336 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [128] => WP_Post Object ( [ID] => 3331 [post_author] => 6 [post_date] => 2021-06-30 12:09:31 [post_date_gmt] => 2021-06-30 12:09:31 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:55:43 [post_modified_gmt] => 2023-01-05 14:55:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3331 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [129] => WP_Post Object ( [ID] => 3329 [post_author] => 6 [post_date] => 2021-06-30 12:04:02 [post_date_gmt] => 2021-06-30 12:04:02 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-09 13:18:35 [post_modified_gmt] => 2023-01-09 13:18:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3329 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [130] => WP_Post Object ( [ID] => 3327 [post_author] => 6 [post_date] => 2021-06-30 11:47:34 [post_date_gmt] => 2021-06-30 11:47:34 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-05 13:58:59 [post_modified_gmt] => 2023-01-05 13:58:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3327 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [131] => WP_Post Object ( [ID] => 3326 [post_author] => 6 [post_date] => 2021-06-30 11:35:26 [post_date_gmt] => 2021-06-30 11:35:26 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:05:33 [post_modified_gmt] => 2023-03-28 14:05:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3326 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [132] => WP_Post Object ( [ID] => 3323 [post_author] => 6 [post_date] => 2021-06-30 11:15:16 [post_date_gmt] => 2021-06-30 11:15:16 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-09 13:12:53 [post_modified_gmt] => 2023-01-09 13:12:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3323 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [133] => WP_Post Object ( [ID] => 3321 [post_author] => 6 [post_date] => 2021-06-30 11:12:36 [post_date_gmt] => 2021-06-30 11:12:36 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-13-2 [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:03:32 [post_modified_gmt] => 2023-01-05 14:03:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3321 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [134] => WP_Post Object ( [ID] => 3318 [post_author] => 6 [post_date] => 2021-06-30 10:46:25 [post_date_gmt] => 2021-06-30 10:46:25 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-10 09:20:27 [post_modified_gmt] => 2023-01-10 09:20:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3318 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [135] => WP_Post Object ( [ID] => 3316 [post_author] => 6 [post_date] => 2021-06-30 10:25:45 [post_date_gmt] => 2021-06-30 10:25:45 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-09 12:51:00 [post_modified_gmt] => 2023-01-09 12:51:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3316 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [136] => WP_Post Object ( [ID] => 3315 [post_author] => 6 [post_date] => 2021-06-30 10:19:01 [post_date_gmt] => 2021-06-30 10:19:01 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-05 14:19:23 [post_modified_gmt] => 2023-01-05 14:19:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3315 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [137] => WP_Post Object ( [ID] => 2909 [post_author] => 6 [post_date] => 2021-05-19 15:13:58 [post_date_gmt] => 2021-05-19 15:13:58 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:42:59 [post_modified_gmt] => 2023-01-10 13:42:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2909 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [138] => WP_Post Object ( [ID] => 2908 [post_author] => 6 [post_date] => 2021-05-19 15:08:05 [post_date_gmt] => 2021-05-19 15:08:05 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:40:09 [post_modified_gmt] => 2023-01-10 13:40:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2908 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [139] => WP_Post Object ( [ID] => 2907 [post_author] => 6 [post_date] => 2021-05-19 14:46:20 [post_date_gmt] => 2021-05-19 14:46:20 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-08-12 15:03:09 [post_modified_gmt] => 2022-08-12 15:03:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2907 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [140] => WP_Post Object ( [ID] => 2893 [post_author] => 6 [post_date] => 2021-05-19 14:40:45 [post_date_gmt] => 2021-05-19 14:40:45 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:17:46 [post_modified_gmt] => 2023-03-28 14:17:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2893 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [141] => WP_Post Object ( [ID] => 2892 [post_author] => 6 [post_date] => 2021-05-14 19:30:23 [post_date_gmt] => 2021-05-14 19:30:23 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 14:00:44 [post_modified_gmt] => 2023-01-10 14:00:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [142] => WP_Post Object ( [ID] => 2890 [post_author] => 6 [post_date] => 2021-05-14 19:14:07 [post_date_gmt] => 2021-05-14 19:14:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:14:51 [post_modified_gmt] => 2023-01-10 11:14:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [143] => WP_Post Object ( [ID] => 2889 [post_author] => 6 [post_date] => 2021-05-14 19:09:07 [post_date_gmt] => 2021-05-14 19:09:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-10 12:43:57 [post_modified_gmt] => 2023-01-10 12:43:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2889 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [144] => WP_Post Object ( [ID] => 2885 [post_author] => 5 [post_date] => 2021-05-14 18:17:37 [post_date_gmt] => 2021-05-14 18:17:37 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:16:30 [post_modified_gmt] => 2023-01-10 13:16:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2885 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [145] => WP_Post Object ( [ID] => 1221 [post_author] => 6 [post_date] => 2020-05-22 20:09:53 [post_date_gmt] => 2020-05-22 20:09:53 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfpi3-template-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:12:53 [post_modified_gmt] => 2023-01-17 17:12:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [146] => WP_Post Object ( [ID] => 1205 [post_author] => 6 [post_date] => 2020-05-22 19:33:17 [post_date_gmt] => 2020-05-22 19:33:17 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-19 12:05:50 [post_modified_gmt] => 2023-01-19 12:05:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [147] => WP_Post Object ( [ID] => 1204 [post_author] => 6 [post_date] => 2020-05-22 19:31:46 [post_date_gmt] => 2020-05-22 19:31:46 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:26:09 [post_modified_gmt] => 2023-01-19 09:26:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [148] => WP_Post Object ( [ID] => 1203 [post_author] => 6 [post_date] => 2020-05-22 19:30:52 [post_date_gmt] => 2020-05-22 19:30:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-13 14:49:22 [post_modified_gmt] => 2023-01-13 14:49:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [149] => WP_Post Object ( [ID] => 1202 [post_author] => 6 [post_date] => 2020-05-22 19:28:49 [post_date_gmt] => 2020-05-22 19:28:49 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-13 14:47:56 [post_modified_gmt] => 2023-01-13 14:47:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [150] => WP_Post Object ( [ID] => 1159 [post_author] => 6 [post_date] => 2020-05-21 23:14:15 [post_date_gmt] => 2020-05-21 23:14:15 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:13:30 [post_modified_gmt] => 2023-01-17 17:13:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [151] => WP_Post Object ( [ID] => 996 [post_author] => 7 [post_date] => 2020-05-18 19:58:18 [post_date_gmt] => 2020-05-18 19:58:18 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:16:23 [post_modified_gmt] => 2023-01-17 17:16:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [invalid_get] => [is_text_search] => 1 [has_agreement_filters] => [has_any_agreement_filter] => Array ( ) [found_agreements] => [has_provision_filters] => [found_provisions] => 1 [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for: [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue: [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term: [lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type: [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type: [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology: [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage: [issues_by_id:GHIAA2019\MapguideSearch:private] => Array ( [101] => WP_Term Object ( [term_id] => 101 [name] => Access plans & principles [slug] => equitable-access [term_group] => 0 [term_taxonomy_id] => 101 [taxonomy] => issue [description] => [parent] => 46 [count] => 29 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [100] => WP_Term Object ( [term_id] => 100 [name] => Affordable pricing [slug] => pricing [term_group] => 0 [term_taxonomy_id] => 100 [taxonomy] => issue [description] => [parent] => 46 [count] => 28 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [66] => WP_Term Object ( [term_id] => 66 [name] => Benefit sharing [slug] => benefit-revenue-sharing [term_group] => 0 [term_taxonomy_id] => 66 [taxonomy] => issue [description] => [parent] => 53 [count] => 9 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [53] => WP_Term Object ( [term_id] => 53 [name] => Business model [slug] => business-model [term_group] => 0 [term_taxonomy_id] => 53 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [84] => WP_Term Object ( [term_id] => 84 [name] => Confidentiality [slug] => confidentiality [term_group] => 0 [term_taxonomy_id] => 84 [taxonomy] => issue [description] => [parent] => 49 [count] => 65 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [271] => WP_Term Object ( [term_id] => 271 [name] => Donation [slug] => donation [term_group] => 0 [term_taxonomy_id] => 271 [taxonomy] => issue [description] => [parent] => 46 [count] => 5 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [72] => WP_Term Object ( [term_id] => 72 [name] => Effects of termination [slug] => effect-of-termination [term_group] => 0 [term_taxonomy_id] => 72 [taxonomy] => issue [description] => [parent] => 52 [count] => 49 [filter] => raw [parent_name] => Term & termination [parent_slug] => term-and-termination ) [281] => WP_Term Object ( [term_id] => 281 [name] => Ensuring continuity [slug] => ensuring-continuity [term_group] => 0 [term_taxonomy_id] => 281 [taxonomy] => issue [description] => [parent] => 46 [count] => 34 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [46] => WP_Term Object ( [term_id] => 46 [name] => Equitable Access [slug] => access-to-medicines [term_group] => 0 [term_taxonomy_id] => 46 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [278] => WP_Term Object ( [term_id] => 278 [name] => Governance [slug] => roles-responsibilities [term_group] => 0 [term_taxonomy_id] => 278 [taxonomy] => issue [description] => [parent] => 53 [count] => 51 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [80] => WP_Term Object ( [term_id] => 80 [name] => Indemnification & liability [slug] => indemnity [term_group] => 0 [term_taxonomy_id] => 80 [taxonomy] => issue [description] => [parent] => 50 [count] => 65 [filter] => raw [parent_name] => Liability [parent_slug] => liability ) [257] => WP_Term Object ( [term_id] => 257 [name] => Information sharing [slug] => information-sharing-information-sharing [term_group] => 0 [term_taxonomy_id] => 257 [taxonomy] => issue [description] => [parent] => 49 [count] => 55 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [109] => WP_Term Object ( [term_id] => 109 [name] => Insurance [slug] => insurance [term_group] => 0 [term_taxonomy_id] => 109 [taxonomy] => issue [description] => [parent] => 50 [count] => 37 [filter] => raw [parent_name] => Liability [parent_slug] => liability ) [48] => WP_Term Object ( [term_id] => 48 [name] => Intellectual Property [slug] => ip-ownership [term_group] => 0 [term_taxonomy_id] => 48 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [50] => WP_Term Object ( [term_id] => 50 [name] => Liability [slug] => liability [term_group] => 0 [term_taxonomy_id] => 50 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [88] => WP_Term Object ( [term_id] => 88 [name] => License Grants [slug] => license-grants [term_group] => 0 [term_taxonomy_id] => 88 [taxonomy] => issue [description] => [parent] => 48 [count] => 66 [filter] => raw [parent_name] => Intellectual Property [parent_slug] => ip-ownership ) [87] => WP_Term Object ( [term_id] => 87 [name] => Ownership of IP [slug] => ownership-ip [term_group] => 0 [term_taxonomy_id] => 87 [taxonomy] => issue [description] => [parent] => 48 [count] => 53 [filter] => raw [parent_name] => Intellectual Property [parent_slug] => ip-ownership ) [70] => WP_Term Object ( [term_id] => 70 [name] => Payment Structures [slug] => royalties-and-payments [term_group] => 0 [term_taxonomy_id] => 70 [taxonomy] => issue [description] => [parent] => 53 [count] => 50 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [102] => WP_Term Object ( [term_id] => 102 [name] => Preparedness & response [slug] => outbreak-preparedness [term_group] => 0 [term_taxonomy_id] => 102 [taxonomy] => issue [description] => [parent] => 46 [count] => 9 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [268] => WP_Term Object ( [term_id] => 268 [name] => Product supply [slug] => supply-purchase-of-products [term_group] => 0 [term_taxonomy_id] => 268 [taxonomy] => issue [description] => [parent] => 53 [count] => 30 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [49] => WP_Term Object ( [term_id] => 49 [name] => Protecting & sharing information [slug] => information-sharing [term_group] => 0 [term_taxonomy_id] => 49 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [90] => WP_Term Object ( [term_id] => 90 [name] => Protection of IP [slug] => protection-results [term_group] => 0 [term_taxonomy_id] => 90 [taxonomy] => issue [description] => [parent] => 48 [count] => 42 [filter] => raw [parent_name] => Intellectual Property [parent_slug] => ip-ownership ) [290] => WP_Term Object ( [term_id] => 290 [name] => Publication of Results [slug] => publication-of-results [term_group] => 0 [term_taxonomy_id] => 290 [taxonomy] => issue [description] => [parent] => 49 [count] => 39 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [56] => WP_Term Object ( [term_id] => 56 [name] => Regulatory strategy [slug] => regulatory-strategy [term_group] => 0 [term_taxonomy_id] => 56 [taxonomy] => issue [description] => [parent] => 53 [count] => 37 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [81] => WP_Term Object ( [term_id] => 81 [name] => Representations & Warranties [slug] => warranties [term_group] => 0 [term_taxonomy_id] => 81 [taxonomy] => issue [description] => [parent] => 50 [count] => 56 [filter] => raw [parent_name] => Liability [parent_slug] => liability ) [86] => WP_Term Object ( [term_id] => 86 [name] => Technology transfer [slug] => technology-transfer [term_group] => 0 [term_taxonomy_id] => 86 [taxonomy] => issue [description] => [parent] => 49 [count] => 25 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [52] => WP_Term Object ( [term_id] => 52 [name] => Term & termination [slug] => term-and-termination [term_group] => 0 [term_taxonomy_id] => 52 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [76] => WP_Term Object ( [term_id] => 76 [name] => Term of agreement [slug] => term-of-agreement [term_group] => 0 [term_taxonomy_id] => 76 [taxonomy] => issue [description] => [parent] => 52 [count] => 53 [filter] => raw [parent_name] => Term & termination [parent_slug] => term-and-termination ) [74] => WP_Term Object ( [term_id] => 74 [name] => Termination & withdrawal [slug] => termination-and-withdrawal [term_group] => 0 [term_taxonomy_id] => 74 [taxonomy] => issue [description] => [parent] => 52 [count] => 51 [filter] => raw [parent_name] => Term & termination [parent_slug] => term-and-termination ) [282] => WP_Term Object ( [term_id] => 282 [name] => Territory access commitments [slug] => territory-access-commitments [term_group] => 0 [term_taxonomy_id] => 282 [taxonomy] => issue [description] => [parent] => 46 [count] => 33 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) ) [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array ( [equitable-access] => WP_Term Object ( [term_id] => 101 [name] => Access plans & principles [slug] => equitable-access [term_group] => 0 [term_taxonomy_id] => 101 [taxonomy] => issue [description] => [parent] => 46 [count] => 29 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [pricing] => WP_Term Object ( [term_id] => 100 [name] => Affordable pricing [slug] => pricing [term_group] => 0 [term_taxonomy_id] => 100 [taxonomy] => issue [description] => [parent] => 46 [count] => 28 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [benefit-revenue-sharing] => WP_Term Object ( [term_id] => 66 [name] => Benefit sharing [slug] => benefit-revenue-sharing [term_group] => 0 [term_taxonomy_id] => 66 [taxonomy] => issue [description] => [parent] => 53 [count] => 9 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [business-model] => WP_Term Object ( [term_id] => 53 [name] => Business model [slug] => business-model [term_group] => 0 [term_taxonomy_id] => 53 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [confidentiality] => WP_Term Object ( [term_id] => 84 [name] => Confidentiality [slug] => confidentiality [term_group] => 0 [term_taxonomy_id] => 84 [taxonomy] => issue [description] => [parent] => 49 [count] => 65 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [donation] => WP_Term Object ( [term_id] => 271 [name] => Donation [slug] => donation [term_group] => 0 [term_taxonomy_id] => 271 [taxonomy] => issue [description] => [parent] => 46 [count] => 5 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [effect-of-termination] => WP_Term Object ( [term_id] => 72 [name] => Effects of termination [slug] => effect-of-termination [term_group] => 0 [term_taxonomy_id] => 72 [taxonomy] => issue [description] => [parent] => 52 [count] => 49 [filter] => raw [parent_name] => Term & termination [parent_slug] => term-and-termination ) [ensuring-continuity] => WP_Term Object ( [term_id] => 281 [name] => Ensuring continuity [slug] => ensuring-continuity [term_group] => 0 [term_taxonomy_id] => 281 [taxonomy] => issue [description] => [parent] => 46 [count] => 34 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [access-to-medicines] => WP_Term Object ( [term_id] => 46 [name] => Equitable Access [slug] => access-to-medicines [term_group] => 0 [term_taxonomy_id] => 46 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [roles-responsibilities] => WP_Term Object ( [term_id] => 278 [name] => Governance [slug] => roles-responsibilities [term_group] => 0 [term_taxonomy_id] => 278 [taxonomy] => issue [description] => [parent] => 53 [count] => 51 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [indemnity] => WP_Term Object ( [term_id] => 80 [name] => Indemnification & liability [slug] => indemnity [term_group] => 0 [term_taxonomy_id] => 80 [taxonomy] => issue [description] => [parent] => 50 [count] => 65 [filter] => raw [parent_name] => Liability [parent_slug] => liability ) [information-sharing-information-sharing] => WP_Term Object ( [term_id] => 257 [name] => Information sharing [slug] => information-sharing-information-sharing [term_group] => 0 [term_taxonomy_id] => 257 [taxonomy] => issue [description] => [parent] => 49 [count] => 55 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [insurance] => WP_Term Object ( [term_id] => 109 [name] => Insurance [slug] => insurance [term_group] => 0 [term_taxonomy_id] => 109 [taxonomy] => issue [description] => [parent] => 50 [count] => 37 [filter] => raw [parent_name] => Liability [parent_slug] => liability ) [ip-ownership] => WP_Term Object ( [term_id] => 48 [name] => Intellectual Property [slug] => ip-ownership [term_group] => 0 [term_taxonomy_id] => 48 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [liability] => WP_Term Object ( [term_id] => 50 [name] => Liability [slug] => liability [term_group] => 0 [term_taxonomy_id] => 50 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [license-grants] => WP_Term Object ( [term_id] => 88 [name] => License Grants [slug] => license-grants [term_group] => 0 [term_taxonomy_id] => 88 [taxonomy] => issue [description] => [parent] => 48 [count] => 66 [filter] => raw [parent_name] => Intellectual Property [parent_slug] => ip-ownership ) [ownership-ip] => WP_Term Object ( [term_id] => 87 [name] => Ownership of IP [slug] => ownership-ip [term_group] => 0 [term_taxonomy_id] => 87 [taxonomy] => issue [description] => [parent] => 48 [count] => 53 [filter] => raw [parent_name] => Intellectual Property [parent_slug] => ip-ownership ) [royalties-and-payments] => WP_Term Object ( [term_id] => 70 [name] => Payment Structures [slug] => royalties-and-payments [term_group] => 0 [term_taxonomy_id] => 70 [taxonomy] => issue [description] => [parent] => 53 [count] => 50 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [outbreak-preparedness] => WP_Term Object ( [term_id] => 102 [name] => Preparedness & response [slug] => outbreak-preparedness [term_group] => 0 [term_taxonomy_id] => 102 [taxonomy] => issue [description] => [parent] => 46 [count] => 9 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) [supply-purchase-of-products] => WP_Term Object ( [term_id] => 268 [name] => Product supply [slug] => supply-purchase-of-products [term_group] => 0 [term_taxonomy_id] => 268 [taxonomy] => issue [description] => [parent] => 53 [count] => 30 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [information-sharing] => WP_Term Object ( [term_id] => 49 [name] => Protecting & sharing information [slug] => information-sharing [term_group] => 0 [term_taxonomy_id] => 49 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [protection-results] => WP_Term Object ( [term_id] => 90 [name] => Protection of IP [slug] => protection-results [term_group] => 0 [term_taxonomy_id] => 90 [taxonomy] => issue [description] => [parent] => 48 [count] => 42 [filter] => raw [parent_name] => Intellectual Property [parent_slug] => ip-ownership ) [publication-of-results] => WP_Term Object ( [term_id] => 290 [name] => Publication of Results [slug] => publication-of-results [term_group] => 0 [term_taxonomy_id] => 290 [taxonomy] => issue [description] => [parent] => 49 [count] => 39 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [regulatory-strategy] => WP_Term Object ( [term_id] => 56 [name] => Regulatory strategy [slug] => regulatory-strategy [term_group] => 0 [term_taxonomy_id] => 56 [taxonomy] => issue [description] => [parent] => 53 [count] => 37 [filter] => raw [parent_name] => Business model [parent_slug] => business-model ) [warranties] => WP_Term Object ( [term_id] => 81 [name] => Representations & Warranties [slug] => warranties [term_group] => 0 [term_taxonomy_id] => 81 [taxonomy] => issue [description] => [parent] => 50 [count] => 56 [filter] => raw [parent_name] => Liability [parent_slug] => liability ) [technology-transfer] => WP_Term Object ( [term_id] => 86 [name] => Technology transfer [slug] => technology-transfer [term_group] => 0 [term_taxonomy_id] => 86 [taxonomy] => issue [description] => [parent] => 49 [count] => 25 [filter] => raw [parent_name] => Protecting & sharing information [parent_slug] => information-sharing ) [term-and-termination] => WP_Term Object ( [term_id] => 52 [name] => Term & termination [slug] => term-and-termination [term_group] => 0 [term_taxonomy_id] => 52 [taxonomy] => issue [description] => [parent] => 0 [count] => 0 [filter] => raw [parent_name] => [parent_slug] => ) [term-of-agreement] => WP_Term Object ( [term_id] => 76 [name] => Term of agreement [slug] => term-of-agreement [term_group] => 0 [term_taxonomy_id] => 76 [taxonomy] => issue [description] => [parent] => 52 [count] => 53 [filter] => raw [parent_name] => Term & termination [parent_slug] => term-and-termination ) [termination-and-withdrawal] => WP_Term Object ( [term_id] => 74 [name] => Termination & withdrawal [slug] => termination-and-withdrawal [term_group] => 0 [term_taxonomy_id] => 74 [taxonomy] => issue [description] => [parent] => 52 [count] => 51 [filter] => raw [parent_name] => Term & termination [parent_slug] => term-and-termination ) [territory-access-commitments] => WP_Term Object ( [term_id] => 282 [name] => Territory access commitments [slug] => territory-access-commitments [term_group] => 0 [term_taxonomy_id] => 282 [taxonomy] => issue [description] => [parent] => 46 [count] => 33 [filter] => raw [parent_name] => Equitable Access [parent_slug] => access-to-medicines ) ) [filter_issues:GHIAA2019\MapguideSearch:private] => Array ( ) )